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     Infertility, the inability to conceive after one year of unprotected intercourse, affects 
approximately one out of every seven couples in the United States (US).  In the last 
decade, 7.3 million Americans reported using fertility services.  Infertility limits the 
likelihood of a live birth, but has also been associated with other reproductive diseases, 
psychosocial stress, and economic hardship.  An infertility diagnosis can arise from 
female or male factors, or a combination of both.  Currently, the use of assisted 
reproductive technologies (ART) including in vitro fertilization (IVF) is steadily on the 
rise.  
     Human reproduction is a composite of multiple biological responses which occur in 
phases, many of which occur without observation.  Each phase is susceptible to 
exposures to various environmental toxicants, including flame retardants (FR) 
commonly found in furniture foams, carpeting, electronics, and plastics.  Their lack of 
covalent bonds allows for leaching into the surrounding environment and thus lead to 
widespread exposure.   Although some FRs have been phased out of production, they 
persist in the environment and the use of alternative compounds is increasing.  Legacy 
FRs such as polybrominated diphenyl ethers (PBDEs) and replacement FRs like 
organophosphate esters (OPEs), have been widely detected among the US population.  
Laboratory studies suggest PBDEs and OPEs are reproductive toxicants, yet human 
data are lacking.  Furthermore, studies suggest that some PBDE metabolites, such as 
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hydroxylated brominated diphenyl ethers (OH-BDEs), may elicit greater toxic effects 
compared to their respective parent compounds.      
     The three aims of this dissertation were executed using data from a subset of 
couples from the Environment and Reproductive Health (EARTH) study, an existing 
longitudinal pre-conception cohort assessing the impact of environmental, dietary and 
lifestyle factors on fertility among couples from a fertility clinic in Boston.  The first aim 
evaluated the relationships of serum PBDE congeners and OH-BDE metabolites with 
early developmental (intermediate) and pregnancy (clinical) IVF outcomes among 
women seeking fertility treatment.  The second aim investigated the joint effects of 
PBDE and OH-BDE exposure of women and their male partners with intermediate and 
clinical IVF outcomes.  The final aim evaluated (1) whether exposure to OPEs as 
determined by levels of their urinary metabolites, was associated with in-home 
exposures and (2) the associations of OPE metabolites with male fertility. 
     We observed a steady decline in PBDE concentrations over the ten-year study 
period.  Concentrations of all FRs were higher in women compared to their male 
partners.  We observed unexpected positive associations between female PBDE and 
OH-BDE concentrations and clinical IVF outcomes.  However, when also accounting for 
male exposure, effect estimates diminished and lost statistical significance.  We 
observed a slight increase in OPE metabolite concentrations in the final years of 
recruitment.  The use of several personal care and household products were associated 
with elevated OPE metabolite concentrations among couples.  However, associations of 
OPE metabolites with male fertility were weak and inconsistent. 
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     This dissertation highlights the persistence of PBDEs and their metabolites despite 
being phased out of production.  Furthermore, our novel study design underscores the 
importance of considering male exposures when evaluating the relationships of 
environmental toxicants with fertility and pregnancy outcomes.  This work highlights the 
persistence of FRs and suggests PCPs can be an important source of OPE exposure 








Impact of Infertility 
          Infertility, the inability to conceive after one year of unprotected intercourse, 
affects one out of every seven couples in the United States (US), while 10% of couples 
experience some type of difficulty trying to conceive 1,2.  Between 2006-2010, a US 
national survey reported 12% of women are burdened by impaired fecundity, the 
biological capacity to become pregnant 3.  The underlying cause of infertility may be 
related to female or male factors or a combination of both. Known causes of female 
infertility include anatomical, hormonal, lifestyle, environmental, or unexplained factors 
4.  Advanced maternal age has also been identified as a negative predictor of both 
fecundity and fertility, which is cause for concern as the number of women over the age 
of 30 having their first child has increased 20% in the last 30 years 5–8.  In 2002, 
approximately 3.2 million US men reported ever using fertility services 9.  However, a 
national survey study suggests this to be an underestimate for the US population as 
male factor infertility is likely to be underdiagnosed 9,10. The cost of male factor infertility 
alone was $17 million US dollars in the year 2000, which does not include the additional 
$18 billion for assisted reproductive technology (ART) treatment 11.  To date, a semen 
analysis measuring sperm count, concentration, morphology, and volume remains the 
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primary evaluation for male factor infertility 10,12.  Semen quality is also associated with 
other various health outcomes including testicular cancer and decreased life expectancy 
13,14.   A recent meta-analysis found an approximate 50% reduction in total sperm count 
and sperm concentration among men from Western countries over the last several 
decades, irrespective of infertility diagnosis 15.  Infertility not only prevents live birth, but 
has been associated with reproductive cancers, psychosocial stress, financial burden, 
and life expectancy 13,14,16–18.   
          Since 1981, ART has aided those suffering from infertility 19.  A large proportion of 
ART is through in vitro fertilization (IVF), a process of in vitro oocyte fertilization and 
embryo culture, followed by embryo transfer through the cervix into the uterus 2.  In 
2013, approximately 7.3 million people reported ever using infertility services 3.  These 
numbers are likely to rise as the number of ART cycles (excluding those initially 
intended for cryopreservation) in the US increased 13% from 2013 to 2015 19,20.  
Advanced maternal age, genetic risk factors, other health issues, and psychosocial 
factors can impair fertility and increase the use of ART services 7,21.  Exposure to 
environmental toxicants has also been associated with infertility 22.  In the European 
Union (EU), health care costs associated with infertility as a result of environmental 
exposures alone was estimated at €1.8 billion euros 23. 
 
 
Flame retardant exposure in the general population 
Polybrominated diphenyl ethers (PBDEs) 
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          Over the last 75 years, flame retardants (FRs) with ranging chemical 
compositions have been added to thousands of consumer products to protect people, 
property, and the environment 24.  FRs operate by several mechanisms including 
reducing ignition and suppressing the spread of fire.  Approximately 2.5 billion pounds 
of FRs are either manufactured or imported into the US annually 25.  Additive FRs lack a 
covalent bond to their original materials which allows them to leach into the environment 
26.  The most prominent class of FRs added to consumer products from the 1970s to 
mid-2000s were polybrominated diphenyl ethers (PBDEs) due to their high efficiency 
and cost effectiveness 27.  PBDEs were added to carpeting, electronics, and plastics 
and constitute up to 30% of product by weight 26,28,29.  There are 209 specific PBDE 
congeners with various bromine substitution patterns, yet the most frequently detected 
congeners in the environment and humans are from three commercial mixtures referred 
to as, Penta-, Octa-, and Deca- brominated diphenyl ether (BDE).  The distribution of 
specific congeners by weight for the three commercial mixtures is presented in Figure 
l.1.  However, due to toxicity in humans and ecosystems, the US voluntarily phased out 
the use of PentaBDE and OctaBDE mixtures in 2004 while DecaBDE was not phased 
out until 2013 30.        
          Pharmacokinetic models suggest the daily body burden of PBDEs in the early 
2000s to be 7.7ng/kg body weight and 33.8 ng/kg lipid weight 31.  PBDEs are lipophilic 
with half-lives ranging from weeks to years depending on the specific congener and 
bioaccumulate in the environment, which has led to ubiquitous exposure 32. Typically, 
PBDEs with a lower degree of bromination are more resilient to biological degradation 
and continue to persist in the environment 33,34.  The primary route/pathway of exposure 
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in the US is via dust ingestion from indoor environments, although exposure through 
diets high in poultry and red meat is most prominent in the EU 30,31,35.  Congeners from 
the PentaBDE mixture have been frequently detected (67-100%) in dust samples from 
homes and offices in Boston, MA 36,37.  Similarly, congeners 47, 99, 100, 153, and 154 
are the most frequently detected in humans 30.  However, PBDE concentrations have 
been decreasing over time.  The National Health and Nutrition Examination Survey 
(NHANES) observed decreases for congeners 47, 99, and 100 from 2005-2014 38. 
 
Hydroxylated polybrominated diphenyl ethers (OH-BDEs) 
          In mammals, hydroxylated-BDEs (OH-BDEs) are formed through oxidative 
metabolism of PBDEs via cytochrome P450 (CYPs) 39.  However, OH-BDEs are also 
biogenic and produced in marine environments and contribute to internal exposure 
through seafood consumption 40.  Similar to their parent compounds, OH-BDEs are 
lipophilic and have been detected in the serum of adults.  The most frequently detected 
metabolites in humans are 3-OH-BDE47, 5-OH-BDE47, 6-OH-BDE47, and 4-OH-
BDE49 39,41–43.  Limited human studies to date have assessed the toxicity of OH-BDEs.   
However, several laboratory studies suggest OH-BDEs act as endocrine disruptors and 
elicit greater toxic responses compared to PBDEs 44–47.  One study found OH-BDEs to 
elicit a significantly greater thyroid hormone responses compared to PBDEs 48.  Another 
study observed OH-BDEs inhibit transthyretin and estradiol-sulfotransferase 160-1600 
and 2.2-200 times higher compared to BDE47, one of several parent compounds 49.  A 
study of pubertal boys observed no comparable differences in concentrations between 
parent compound and metabolite whereas a study of Japanese women found 
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concentrations of 6-OH-BDE47 to be 20-fold higher than one of its parent compounds, 
BDE47 41,50.  
 
Organophosphate esters (OPEs) 
          Since the phase-out of PBDEs in the mid-2000s, the prevalence of 
organophosphate esters (OPEs) has risen drastically and they are increasingly being 
used as replacement FRs in furniture foams, baby products, cars, electronics, and 
carpeting 51–54.  However, some non-chlorinated alkyl and aryl phosphates are used as 
plasticizers and antifoaming agents 55–57.  Triphenyl phosphate (TPHP), a non-
halogenated aryl phosphate, and chlorinated alkyl esters such as tris(2-chloroethyl) 
phosphate (TCEP), and tris(1,3-dichloroisopropyl) phosphate (TDCIPP) are commonly 
used to comply with flammability standards and frequently added to lacquers, paints, 
glues, and hydraulic fluids 58,59.  As the use of PBDEs diminished, the preference for 
OPEs increased and in 2008, they became a high production volume chemical; US 
production is projected to reach 50,000 tons in 2020 60.     
          During manufacturing, OPEs are physically mixed with other compounds and not 
covalently bound to the product(s).  The lack of a covalent bond allows these semi-
volatile compounds to escape into the environment via leaching, abrasion, or 
volatilization 58,61,62.  Exposure to OPEs is dependent upon their respective 
physicochemical properties and specific application.  OPEs have been detected in the 
dust of homes, cars, and offices and primary exposure is likely through dust ingestion 
31,35,36 .  Recent studies suggest possible routes/pathways through inhalation and 
dermal absorption also contribute to exposure 63–66.  Despite half-lives ranging from 
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hours to days, metabolites have been detected in nearly 100% of urine samples of 
children and adults 58,62,67,68.  Frequently detected OPE metabolites include bis(1-chloro-
2-propyl) phosphate (BCIPP), bis(1,3-dichloro-2-propyl) phosphate (BDCIPP), diphenyl 
phosphate (DPHP), isopropylphenyl phenyl phosphate (ip-PPP), and tert-butylphenyl 
phenyl phosphate (tb-PPP) 67,68.  Exposure to OPEs has been associated with oxidative 
stress, and disruption of endocrine, metabolic, immune, and reproductive systems 
66,69,70.  TCEP and TDCIPP are also known carcinogens 71. 
 
Flame retardants as a reproductive toxicant 
          Several laboratory studies have also examined the effects of PBDEs on 
reproduction, primarily through endocrine disruption 72,73.  Male rats exposed during 
gestation to low doses of BDE99 (60 or 300 µg) had reduced sperm and spermatid 
counts, while female offspring experienced a mixture of up and down regulation of 
estrogen receptors 74,75.  An analysis in a previous sample of men (n=24) from the 
Environment and Reproductive Health (EARTH) cohort found a 30% decrease in follicle 
stimulating hormone (FSH) and luteinizing hormone (LH) levels in association with 
congeners 47, 99 and 100 measured in house dust 76.  However, all congeners were 
positively associated with an increase in inhibin B (30%) and sex hormone binding 
globulin (SHBG) (18%).  A larger follow up study observed an increase in SHBG, 
estradiol (E2), free thyroxine (T4) and total (triiodothyronine) T3, yet decreasing FSH 
with an interquartile range (IQR) increase in congeners 47, 99, and 100 36.  BDE47 
concentrations in serum was also associated with increased testosterone levels among 
sport fisherman (n=405) of the Great Lakes 77.   
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     Few human studies have investigated the relationship of PBDEs and female 
reproductive health.  However, longer menstrual cycles (>32 days) were associated with 
increased levels of BDE153 in breast milk 78.  Detectable concentrations of serum 
BDE153 was also associated with an increase in the odds of failed implantation among 
a sample of women (n=65) seeking IVF treatment in Boston, MA 79.  In a study of 
women in California, congeners 47, 99, 100, 153, and their sum measured in serum 
were all associated with a longer time to pregnancy (TTP) 26.  Associations of PBDE 
exposure with semen quality are mixed.  While some report associations of decreased 
motility and morphology, others have observed no associations 80–82.  However, the 
inconclusive findings could potentially be a result of the cross-sectional study design.  
Studies investigating the association of combined PBDE exposure of couples (male and 
female) exposure and fertility outcomes are lacking.  
          To date, studies assessing the reproductive health effects of OPEs are limited, 
yet animal and in vitro studies suggest these compounds act as endocrine disrupting 
chemicals.  A study of TPHP and TCEP in mice observed a disruption of gene 
expression for testosterone synthesis and oxidative stress, while an in vitro study of 
mouse Leydig cells observed a disruption in steroid production 83,84.  A small study of 
US men detected inverse relationships of urinary metabolite concentrations of BDCPP 
and DPHP with sperm concentration and motility 85.  Paternal urinary concentrations of 
BDCIPP was associated with a decrease in fertilization among couples seeking fertility 
treatment 86.  However, among a sample of women seeking fertility treatment, the sum 
of several OPEs (BDCIPP, DPHP, ip-PPP, and tb-PPP) measured in urine was 
associated with declines in implantation, clinical pregnancy, and live birth 69. 
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           Despite the high prevalence of exposure and laboratory studies suggesting 
PBDEs are a reproductive toxicant, human fertility studies are lacking.  Most research to 
date has focused on the disruption of reproductive hormones.  Only one study (n=65) 
has studied PBDEs among the IVF population, and was solely focused on embryo 
implantation 79.  Similarly, few studies have assessed the role of PBDEs in males during 
IVF.  To date, no studies have assessed the reproductive toxicity of PBDEs in 
comparison to their hydroxylated metabolites.  However, in vitro models have shown 
OH-BDEs to be estrogen agonist and genotoxic 46,87,88. 
  Studies assessing the health effects of OPEs are limited, yet laboratory studies 
also suggest these compounds act as endocrine disrupting chemicals.  While the 
majority of human studies have focused on exposure of children and pregnant women, 
only one small study has evaluated OPE exposure with male fertility outcomes 85.  While 
OPEs have been detected in dust, no study has assessed their relationship with 
household products (HP), and studies with personal care products (PCPs) are limited.  
One study identified TPHP in eight out of ten nail polish samples and observed a 7-fold 
increase in DPHP (metabolite of TPHP) after polish application (n=26) 56.   
 
Specific AIMS 
Human reproduction is multifaceted, and each stage is susceptible to various 
environmental toxicants to which humans are exposed, including FRs.  The aim of this 
dissertation is to build upon the limited existing knowledge of the reproductive toxicity of 
FRs and to identify the specific biological endpoints these insults may be associated 
with among couples seeking fertility treatment.  A conceptual diagram outlining the 
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specific aims of this dissertation is illustrated in Figure I.2.  The first two aims of this 
dissertation will build upon existing research of PBDE exposure and couples undergoing 
IVF by (1) focusing on more intermediate endpoints (i.e. response to hormone 
interventions, number of oocytes retrieved, and embryo quality) of IVF among females 
and (2) assessing PBDE and OH-BDE exposure among ‘couples’ rather than females 
and males separately.  The third aim of this dissertation will (1) expand upon the few 
studies assessing the reproductive toxicity of OPEs in humans and (2) determine if 
certain PCPs and HPs are predictive of OPE exposure using a repeated measures 
study design. 
   
Specific Aim #1.  To investigate the relationship between maternal serum 
concentrations of PBDEs and OH-BDEs with IVF outcomes.  More specifically, to 
evaluate the association of congeners: 47, 99, 100, 154, and 153 and OH-BDEs: 4-OH-
BDE49, 6-OH-BDE47, 5-OH-BDE47, 3-OH-BDE47 with intermediate IVF outcomes 
using generalized linear mixed models (GLMM) with random effects and cluster 
weighted generalized estimating equations (CWGEE) models. 
Hypothesis #1:  Increased PBDE concentrations in maternal serum will be negatively 
associated with IVF outcomes. 
Hypothesis #2:  OH-BDEs will have stronger associations IVF outcomes compared to 
PBDEs.  
 
Specific Aim #2: To investigate the joint relationship between PBDE and OH-BDE 
concentrations in both maternal and paternal serum with IVF outcomes.  Specifically, to 
10 
 
evaluate the association of paternal PBDE and OH-BDE concentrations in serum with 
fertilization rate and clinical IVF endpoints while also adjusting for female serum 
concentrations and covariates using GLMM and CWGEE. 
Hypothesis #3:  The joint effects (compared to each individually) of serum PBDEs in 
‘couples’ serum will have stronger associations with negative clinical outcomes 
compared to individual exposure. 
Hypothesis #4:  The joint effects of OH-BDEs in ‘couples’ will have stronger 
associations with negative clinical outcomes compared to PBDEs. 
 
Specific Aim # 3: To investigate the relationship between men and women seeking 
fertility treatments and exposure to five urinary OPE metabolites: BCIPP, BDCIPP, 
DPHP, ip-PPP, and tb-PPP.  Product use will be identified from patient questionnaires 
as predictors of OPE metabolite concentrations in urine.  Male fertility parameters 
(sperm count, concentration, motility, and morphology) were used to assess the 
relationship with OPE metabolites.  
Hypothesis #5:  Reported use of certain household and personal care products will be 
predictive of elevated exposure concentrations of urinary OPE metabolites in females 
and males.              
Hypothesis #6:  Increased exposure to urinary PFR metabolites will be negatively 







          This dissertation is comprised of a subset of study participants from the EARTH 
study, an established longitudinal prospective pre-conception cohort of couples from a 
fertility center where we study the impacts of environmental, dietary, and lifestyle factors 
on reproductive health.  Women (n=230) and their respective male partners (n=229) 
were recruited at the Massachusetts General Hospital (MGH) fertility center in Boston, 
MA between 2005-2016.  Selected fertility center characteristics are described in Tables 
I.1 and I.2. Among all ART cycles at MGH in 2013, 100% utilized IVF (n=803 cycles). 
Approximately 50% of those cycles utilized intracytoplasmic sperm injection (ICSI) or 
preimplantation genetic diagnosis (PGD) 89. Participants were recruited at their initial 
visit to MGH fertility center regardless of treatment.  Questionnaires were administered 
to collect demographic information (i.e. age, race/ethnicity, education level) at study 
entry.   Both men (18-55 yrs.) and women (18-46 yrs.) were eligible to participate.  
However, men who had previously undergone a vasectomy were ineligible. Participants 
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Table I. 1. Selected Massachusetts General Hospital (MGH) fertility center pregnancy 
success rates from fresh embryos from patient’s oocytes, 2013 
 
IVF cycles (n=803)  
  
Procedure  
     ICSI 
     Unstimulated 







     Female factor 
     Male factor 
     Female & male factor 
     Other factor 








ICSI: Intracytoplasmic sperm injection; PGD: Preimplantation genetic diagnosis; Female factors include: 
tubal, ovulatory dysfunction, diminished ovarian reserve, endometriosis, uterine factor, and multiple 
female factor;  Results modified from the 2013 Clinic Summary Report for MGH 90.  Note: these are 


























Table I. 2. Selected age-stratified outcomes from fresh embryos (non-donor eggs) from 
MGH Fertility Center, 2013. 
 
 Maternal age categories 
 <35 35-37 38-40 41-42 >42 
Number of cycles 215 140 148 83 18 
Cycles resulting in pregnancies (%) 57.7 46.4 36.5 32.5 16.7 
Cycles resulting in live birth (%) 53.0 40.7 29.7 20.5 11.1 
Cycles with elective single embryo transfer (%) 34.9 19.4 3.0 1.4 0 
Implantation rate (%) 49.2 31.3 20.5 10.6 5 
Average number of embryos transferred 1.6 1.8 2.4 3.6 4 
 
 
Results modified from the 2013 Clinic Summary Report for MGH 90.  Note: these are characteristics of all 
MGH fertility clinic patients, not only those in the EARTH study.  Throughout recruitment (2005-2016), 





































Figure I.1. Distribution of specific congener composition for commercial brominated diphenyl ether mixtures. 
 
Adapted from the ASTDR’s Toxicological Profile for Polybrominated Diphenyl Ethers (PBDEs), 2015 
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Figure. I.2. Conceptual diagram of specific aims. 
 
Intermediate IVF outcomes: Total oocyte yield, M2 oocyte yield, endometrial wall thickness, and fertilization rate; Clinical IVF outcomes: 







AIM 1:  Exploring Reproductive Associations of Serum Polybrominated Diphenyl 
Ether and Hydroxylated Brominated Diphenyl Ether Concentrations Among 
Women Undergoing In Vitro Fertilization  
Abstract 
Background: Polybrominated diphenyl ethers (PBDEs) have been voluntarily phased 
out of production in the US and EU due to their persistence and toxicity to humans and 
ecosystems.  PBDEs have been associated with implantation failure among women 
undergoing IVF, yet some animal studies suggest greater toxicity from their metabolites, 
hydroxylated brominated diphenyl ethers (OH-BDEs).  The objective of this study is to 
investigate the associations of serum concentrations of polybrominated diphenyl ethers 
PBDEs and OH-BDEs with in vitro fertilization endpoints (IVF).   
Methods: We evaluated a subset of 215 women (contributing 330 IVF cycles) enrolled 
between 2005-2016 in a longitudinal cohort based at Massachusetts General Hospital 
Fertility Center.  The following PBDEs were quantified:  47, 99, 100, 153, and 154 and 
the following OH-BDEs: 3-OH-BDE47, 5-OH-BDE47, 6-OH-BDE47, and 4-OH-BDE49. 
Clinical endpoints of IVF treatments were abstracted from electronic medical records.  
Associations of log-transformed PBDEs and OH-BDEs with IVF outcomes were 
assessed using multivariable generalized mixed models and cluster weighted 
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generalized estimating equation models adjusted for lipids, age, BMI, race, year of 
sample collection, IVF protocol, and follicle stimulating hormone levels.  
Results: Detection frequencies were highest for congeners 47 and 153 (82% ≥ method 
detection limit (MDL)) and metabolites 3 and 5-OH-BDE47 and 4-OH-BDE49 
(92%>MDL).  PBDE and OH-BDE geometric mean concentrations declined by up to 
80% over the study period.  An interquartile range (IQR) increase in BDE153 was 
associated with an increase in the probability of implantation (Relative risk (RR) =1.26, 
95% CI: 1.16, 1.36), clinical pregnancy (RR= 1.32, 95% CI: 1.19, 1.46), and live birth 
(RR= 1.34; 95% CI: 1.15, 1.54).  An IQR increase in 3 and 5-OH-BDE47 was 
associated with increased probabilities of implantation (RR= 1.52; 95% CI:1.11, 2.09), 
clinical pregnancy (RR= 1.66; 95% CI: 1.17, 2.36), and live birth (RR= 1.61; 95% 
CI:1.07, 2.40).  When models were stratified by race (White (86%)/Other race (14%)), 
associations remained positive for White women, yet inverse associations were 
observed for Other race women.  An IQR increase in BDE47 was associated with a 
46% decreased probability of clinical pregnancy (95% CI: 0.31, 0.95) for Other race 
women. 
Conclusion: Detections of serum concentrations of PBDEs and OH-BDEs were highest 
in the early years of the study and suggests the phase-out of these compounds has 
contributed to a decrease in exposure.  The negative associations found for PBDEs and 
IVF outcomes among other race women suggests the potential for racial disparity.  
Potential racial disparities in PBDE exposure and exploration of alternative flame 
retardants with reproductive health outcomes should be the focus of future 




Approximately 15% of couples in the US and 80 million couples worldwide are 
affected by infertility, defined as the inability to conceive after one year of unprotected 
intercourse 1–3.  The annual number of treatment cycles using assisted reproductive 
technology (ART) increased by 13% from 2013-2015.  In 2016, 1.8% of all live births in 
the US were a result of ART.  Infertility treatment (including diagnosis and sequelae) in 
the US is suspected to cost $5 billion annually, which is easy to conceptualize as one 
cycle of in vitro fertilization (IVF) has an average cost of $12,400.  Environmental 
exposures including particulate matter, heavy metals, pesticides, and persistent organic 
pollutants (POPs) have been associated with infertility 4–6. 
 Among POPs that have been associated with infertility are polybrominated 
diphenyl ethers (PBDEs), a prominent class of flame retardants (FR) found in furniture, 
carpeting, electronics, and plastics 7.  While there are potentially 209 different 
brominated diphenyl ether (BDE) congeners (having various bromine substitution 
patterns), only a handful of congeners are routinely detected in the environment and in 
human tissues, and reflect the dominant congeners present in the commercial mixtures 
referred to as Penta-, Octa-, and Deca- BDE.  The most frequently detected congeners, 
47, 99, 100, 153, and 154 are often found in (but not exclusively) the PentaBDE mixture 
8.  OctaBDE is primarily comprised of congeners 183, 196, 197, and 203 (153 and 154 
can be found in PentaBDE and OctaBDE), while 207 and 208 can be found in both 
OctaBDE and DecaBDE, but  202 and 209 are exclusively found in DecaBDE 7.  Due to 
these mixtures’ toxicity to humans and ecosystems, PentaBDE and OctaBDE mixtures 
were phased out of production in 2004 and DecaBDE mixtures were phased out in 2013 
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9.  During manufacturing, PBDEs are physically added to the polymers and the absence 
of a covalent bond allows them to leach into surrounding environments 10.  Their 
lipophilicity allows them to bioaccumulate in the environment and adipose tissues with 
half-lives ranging from weeks to years depending on the specific congener, which has 
led to widespread detection in serum among women, men, and children in the US 11.  
PBDEs have been highly detected in dust samples from homes, offices, and 
automobiles and it is suspected that approximately 82% of exposure in the US can be 
attributed to house dust, while exposure in Europe is primarily from food 12–14.  
 In mammals, hydroxylated-BDEs (OH-BDEs) are formed through oxidative 
metabolism of PBDEs via cytochrome P450 (CYPs), specifically CYP2B6 15.  OH-BDEs 
are also produced naturally in marine environments and exposure can also be attributed 
to seafood consumption 16.  Like PBDEs, OH-BDEs also accumulate in the body and 
have been detected in human serum in adults and children 17–19. Several laboratory 
studies have also observed greater toxic effects from OH-BDEs compared to their 
parent compounds in regards to endocrine disruption, cytotoxicity, and genotoxicity 20–
24.  The most common metabolites detected in humans are 3-OH-BDE47, 5-OH-BDE47, 
6-OH-BDE47, and 4-OH-BDE49 15,17–19.   
 Elevated levels of PBDEs have been associated with adverse reproductive 
health effects in humans, including endocrine disruption, longer menstrual cycles, and 
TTP 18,25–28.  27.  To date, studies assessing the reproductive health effects of OH-BDEs 
are limited; however, several in vitro studies suggest they act as endocrine disruptors 
and elicit oxidative stress 20,22,23,29.  In our present work we expand upon previous 
studies in a more robust analysis investigating the association of PBDEs and pregnancy 
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outcomes along with, to the best of our knowledge, the first study to assess these 
relationships with OH-BDEs using IVF as a model of intermediate developmental 
endpoints and pregnancy outcomes. 
Methods 
Study Population 
Study participants are a subset of women from the EARTH study, an established 
longitudinal prospective pre-conception cohort study of environmental, dietary, and 
lifestyle impacts on reproductive health 30.  Women (18-46 years) were recruited from 
Massachusetts General Hospital (MGH) Fertility Center.  Approximately 60% of women 
who were approached enrolled in the study 31.  Questionnaires were administered to 
collect demographic information (i.e. age, race/ethnicity, education level) at study entry.  
The present analysis includes 215 women (330 IVF cycles) recruited between 2005-
2016 who contributed their own oocytes and provided a blood sample to quantify 
concentrations of FRs and FR metabolites in serum.  The majority of women completed 
1-2 IVF cycles during follow up.  Research protocols were approved by the ethics and 
Research Committees of MGH, Harvard T.H. Chan School of Public Health, University 
of Michigan, and Duke University.  The study was described in detail to all participants 
and informed consent was obtained from all participants. 
 Clinical protocols and IVF measures 
During each cycle, clinical data was abstracted from the participant’s electronic 
health record.  Clinical protocols and IVF measures have been previously detailed 31,32.  
Briefly, on the third day of the woman’s menstrual cycle, a blood serum sample was 
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drawn to measure follicle stimulating hormone (FSH) and estradiol (E2) concentrations 
at MGH Core Laboratory using an automated electrochemiluminescence immunoassay.  
Peak E2 concentrations, defined as the highest level prior to oocyte retrieval, were 
obtained on the day of trigger with human chorionic gonadotropin (hCG).  Infertility 
diagnosis was established by an MGH physician in accordance with the Society of 
Assisted Reproductive Technology (SART) 33. Upon infertility evaluation including 
infertility diagnosis and other clinical factors, one of three ovarian treatment IVF 
protocols was selected: (1) luteal phase gonadotrophin releasing hormone (GnRH) 
agonist, (2) follicular phase GnRH agonist or “flare” stimulation, or (3) GnRH antagonist 
34.  Throughout gonadotropin stimulation and up to two days prior to oocyte retrieval, 
serum E2, follicle size and counts, and endometrial thickness were monitored for each 
participant 31.  Once lead follicle size approached 16-18 mm and E2 levels reached at 
least 500 pg/mL, oocytes were retrieved.  IVF cycle was defined by oocyte retrieval.  
Following oocyte retrieval, an embryologist counted and classified oocytes per cycle as 
a germinal vesicle, metaphase l, metaphase ll (M2), or degenerated.  Fertilization 
occurred via IVF or intracytoplasmic sperm injection (ICSI), and was confirmed 17-20 
hours later. Fertilization was determined by the presence of a cytoplasmic halo and two 
pronuclei  35,36.  Fertilization rate was established as the number of two pronuclear 
embryos divided by the number of M2 oocytes.  Clinical outcomes were assessed for 
participants who continued with embryo transfer.  Successful implantation for a given 
transfer was confirmed when serum β-hCG levels were > 6 mIU/mL, approximately 17 
days after oocyte retrieval 31.  Clinical pregnancy was defined as the presence of an 
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intrauterine pregnancy via ultrasound (≥ 6 wks. gestation) along with elevated levels of 
β-hCG.  Live birth was defined as the birth of a neonate at or after 24 weeks gestation. 
PBDE and OH-BDE collection and measurement 
Blood samples (5 mL) were collected in washed glass Wheaton vials at the study 
entry clinic visit.  Samples were aliquoted, frozen and stored at -80° C until overnight 
shipment on dry ice to Dr. Stapleton’s lab at Duke University (Durham, NC).  Serum was 
analyzed for five PBDE congeners: 47, 99, 100, 153, and 154 along with four OH-BDE 
metabolites: 4-OH-BDE47, 5-OH-BDE47, 6-OH-BDE47, and 4-OH-BDE49.  Upon 
arrival, samples were weighed and fortified with internal standards (monofluorinated 
BDE 69, 13C BDE 209, and 13C-6-OH-BDE47). Serum was diluted with water and 
formic acid before undergoing sold phase extraction (Oasis HLB, Waters Corp.). A 
50:50 solution of dichloromethane (DCM) and ethyl acetate was used to remove both 
PBDES and OH-BDEs from the SPE column. Samples were then dried and rejuvenated 
with hexane (1 mL) followed by extract cleaning via a 1.0 g silica column.  PBDEs were 
removed with 10 mL of hexane while 10 mL of DCM hexane solution was used for the 
metabolites. Gas chromatography negative chemical ionization mass spectrometry 
methods were used to analyze PBDES while OH-BDEs were measured using liquid 
chromatography tandem mass spectrometry 18. Accuracy of the method was verified by 
extracting a human serum Standard Reference Material (SRM 1957) from the National 
Institute of Standards and Technology.  Measured values were in the range of 73%- 
97% of the certified values.  Metabolites 3-OH-BDE47 and 5-OH-BDE47 are presented 
individually as well as combined due to co-elution problems in a few batches.  Total 
lipids were derived from total serum cholesterol and triglycerides using the following 
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formula: TL (g/l) = [ (TC x 1.12) + (TG x 1.33) + 1.48] where TL= total lipids, TG= serum 
triglycerides, and TC= serum cholesterol 37.  Missing total lipids (n=19) were replaced 
with the median (511.5). 
Statistical analysis 
Demographic and reproductive characteristics for women were calculated using 
medians, interquartile ranges (IQRs), frequencies, and percentages as appropriate.  
Congeners and metabolites below method detection limits (MDL) were imputed to 
MDL/√2 38.  Geometric means (GM), 95% confidence intervals (CIs), and selected 
percentiles were used to describe unadjusted (ng/g serum) and lipid-adjusted (ng/g 
lipid) PBDEs and OH-BDEs. Spearman correlation coefficients were used to assess the 
association among serum congeners and metabolites.  PBDEs and OH-BDEs 
presented as right skewed and were transformed by the natural logarithm for further 
analysis.  Associations of congeners and metabolites with reproductive outcomes were 
confirmed to meet linearity assumptions using bivariate analyses and were treated as 
continuous variables.  Possible demographic confounders included total serum lipids, 
age, body mass index (kg/m2) (BMI), race (White/Other race), education (high 
school/some college, college graduate, graduate degree), and year of exposure sample 
collection.  Reproductive characteristics considered were prior pregnancy, day 3 FSH 
levels (IU/L), initial infertility diagnosis (female factor, male factor, or unexplained), 
previous intrauterine insemination (IUI) (yes/no), previous IVF (yes/no), treatment 
protocol (antagonist, flare, or luteal phase agonist), E2 trigger levels (pmol/L), 
endometrial thickness (mm), and ICSI (yes/no).  Covariates were selected if they were 
associated with exposure in previous cohorts, our cohort, or a predictor of IVF outcomes 
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18,28,39,40.  Final models using unadjusted PBDEs and OH-BDEs were adjusted for total 
serum lipid, age, BMI, race, year of exposure sample collection, day 3 FSH levels, and 
IVF protocol. A missing value (n=1) for day 3 FSH level was replaced with the median 
(6.8 IU/L).   
 We evaluated the associations of PBDEs and OH-BDES with intermediate IVF 
outcomes (total oocyte yield, M2 oocyte yield, endometrial wall thickness, and 
fertilization rate) using multivariable generalized mixed models with random intercepts.  
A Poisson distribution with log link function were designated for oocyte counts while a 
normal distribution with identity link function was designated for endometrial thickness.  
A binomial distribution and logit function were designated for fertilization rate.  
Associations with PBDEs and OH-BDEs with clinical outcomes (implantation, clinical 
pregnancy, and live birth) were evaluated using cluster weighted generalized estimating 
equation (CWGEE) models where the weight was equivalent to the inverse of the 
cluster size (cycle number) 41,42.  CWGEEs have some advantages when  accounting 
for multiple cycles per women (i.e. non-ignorable cluster size),  since they may provide 
more  precise estimates when compared to other common statistical approaches for 
dichotomous IVF outcomes 43.  PBDEs and OH-BDEs were modeled individually as well 
as summed.  Metabolites 3-OH-BDE47 and 5-OH-BDE47 were initially modeled 
individually, however due to co-eluting for some batches we decided to present their 
findings as a collective sum (3-OH-BDE47, 5-OHBDE47, 3-OH-BDE47 & 5-OH-BDE47).  
Original effect estimates are presented in tables, and to increase interpretability, 
outcomes in figures and text were adjusted to represent a percent change in outcome 
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with an IQR increase in PBDE or OH-BDE which was calculated using the formula: 
((75th percentile/25th percentile)β - 1) x 100 44.   
 We conducted several sensitivity analyses. To further explore our observation of 
higher PBDE and OH-BDE concentrations among women in the first half of the study, 
we stratified our analysis by year (<2010, ≥2010) and reran our models.  We also reran 
our models stratified by race (White or Other) as prior studies have observed variability 
in PBDE exposure by race 18.  Analyses were performed using SAS 9.4 (SAS Institute 
Inc., Cary, NC) and R version 3.3.5.  
Results 
Demographic and reproductive characteristics of this cohort (n=215 women) are 
described in Table 1 and are similar to previous subsets from the EARTH cohort 31,35.  
Our sample was comprised of predominantly White women (86%) with a normal BMI 
(median=23) in their mid-thirties (median=35 years).  Few women (28%) reported ever 
smoking and over half had graduate degrees (61%).  Only 36% of women reported 
having a prior pregnancy.  The majority of initial infertility diagnoses were male factor 
(36%), followed by unexplained (35%), then female factor (29%).  More women had 
undergone a previous IUI (39%) compared to IVF (21%).  Median day three FSH levels 
were 6.8 IU/L (IQR: 6.0-8.3).  Considerably more women underwent luteal phase 
agonist protocol (69%), compared to flare (18%), and antagonist (13%).  The median 
peak E2 levels were 1998 pmol/L and endometrial thickness was 10 mm.  
Approximately half of cycles (52%) underwent ICSI. 
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     Distributions of PBDEs and OH-BDEs are presented in Table 2 as unadjusted 
(ng/g serum) and lipid-adjusted (ng/g lipid).  Congeners 47, 100, and 153 were 
frequently detected (70%>MDL).  Concentration levels (GM) of BDE47 and BDE153 
were approximately five times greater than BDEs 99 and 100.  Metabolites 3-OH-
BDE47, co-eluted samples of 3-OH-BDE47 and 5-OH-BDE47, and 4-OH-BDE49 were 
frequently detected (92%>MDL).  The combined concentrations of 3-OH-BDE47 and 5-
OH-BDE47 were the highest (GM= 1.3 ng/g lipid) of all metabolites.  3-OH-BDE47 
concentrations (GM= 0.32 ng/g lipid) were slightly higher compared to 6-OH-BDE47 and 
4-OH-BDE49 (GM= 0.19 ng/g lipid and GM= 0.20 ng/g lipid).   
 Yearly trends of lipid-adjusted PBDE and OH-BDE concentrations (GMs) 
throughout the study are shown in Figure II.1.  Concentrations were highest for BDE47 
(GM=67 ng/g/ lipid) and BDE154 (GM=20 ng/g lipid) in 2005.  BDE99 peaked in 2008 
(GM= 9 ng/g lipid), while BDE100 and BDE153 did not peak until 2009 (GM=8 ng/g lipid 
and GM=54 ng/g lipid).  By 2014, concentrations of congeners 99, 100, and 153 had 
decreased by 66, 63, and 63% (GM=3 ng/g lipid, GM=3 ng/g lipid, and GM=20 ng/g 
lipid, respectively).  Between 2005-2015 concentrations of BDE154 decreased by 50%, 
while concentrations of BDE47 decreased by almost 80%.  Similar trends were 
observed for OH-BDES.  3-OH-BDE47 and 5-OH-BDE47 concentrations decreased by 
80% over the study period, yet had a slight peak in 2010 (GM=37 ng/g lipid).  Although 
initial concentrations of 6-OH-BDE47 and 4-OH-BDE49 were not as high at the 
beginning of the study compared to other metabolites, concentrations still decreased 
substantially (75% and 57%, respectively). 
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 Several demographic and clinical characteristics were associated with PBDE and 
OH-BDE exposure (data not shown).  Correlations between BMI and BDE100 were 
positive (r=0.15), yet negative for BDE153 (r=-0.15).  Other race women had higher 
concentrations of BDE47, BDE99, 3 and 5-OH-BDE47, and 4-OH-BDE49 compared to 
White women.  Current or past smokers had higher concentrations of BDE47 and 
BDE99 than non-smokers.  Nulliparous women had higher concentrations of congeners 
99, 100, and 153.   
 Correlations for lipid-adjusted PBDEs and OH-BDEs (ng/g lipid) are presented in 
Figure II.2.  All PBDEs were significantly correlated with each other.  Correlations were 
strongest for BDE47, BDE99, and BDE100 (0.73-0.85), while correlations for BDE153 
and BDE154 were slightly weaker (0.31-0.53).  Moderate-to-strong correlations (0.39-
0.56) were observed for all OH-BDEs.  Metabolites had the strongest correlations to 
BDE47 (3 and 5-OH-BDE47: r=0.57, 6-OH-BDE47: r=0.47, and 4-OH-BDE49: r=0.64).  
Strong correlations were also observed with 4-OH-BDE49 and BDE99 (r=0.59) and 
BDE100 (r=0.47).  Associations were weakest for BDE154 and 4-OH-BDE49 (r=0.30). 
  No associations were observed for any PBDEs with intermediate IVF outcomes 
(prior to implantation) in unadjusted and adjusted models (Tables II.A.1 and II.A.2).  
However, in adjusted models, an IQR increase of 4-OH-BDE49 was associated with a 
39 and 48% increase (95%CI: 0.5, 94 and 95% CI: 5, 109%, respectively) in total oocyte 
and M2 oocyte yield (Table II.A. 4).   
 Associations of PBDEs and OH-BDEs with clinical IVF outcomes are depicted in 
Figures 3 and 4 and represent the percent change in outcome in relation to an IQR 
increase in PBDE/OH-BDE concentrations.  For example, an IQR increase in BDE153 
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was associated with increased probabilities of implantation, clinical pregnancy, and live 
birth (RR=1.16; 95% CI: 1.16, 1.36, RR= 1.25; 95% CI: 1.16, 1.35, RR= 1.26; 95% CI: 
1.13, 1.41).  An IQR increase in 3 and 5-OH-BDE47 was associated with increased 
probabilities of implantation (RR= 1.28; 95% CI:1.07, 1.53), clinical pregnancy (RR= 
1.35; 95% CI: 1.11, 1.64), and live birth (RR= 1.31; 95% CI:1.04, 1.66).  An IQR 
increase in 6-OH-BDE47 was also associated with a 56% increase in the probabilities of 
both implantation and clinical pregnancy, and an 84% increase in the probability of live 
birth (RR= 1.56, 95% CI:1.14, 2.14, RR= 1.56; 95% CI: 1.12, 2.18, and RR= 1.84, 95% 
CI: 1.26, 2.68, respectively). 
 When stratifying by race (White/Other race), associations with BDE153 remained 
positive for clinical outcomes among White women (Figure II.A.1).  An IQR increase in 
BDE47 was associated with a decreased probability of implantation (36%), clinical 
pregnancy (46%), and live birth (35%) for Other race (RR= 0.64; 95% CI: 0.36, 1.16, 
RR= 0.54; 95% CI: 0.31, 0.95, and RR=0.65; 95% CI: 0.38, 1.13, respectively), while 
associations for White participants remained positive.  We also observed a decrease in 
the probability of clinical outcomes with congeners 99, 100, and 153 for Other race 
women.  We also observed several non-significant changes in models of OH-BDEs with 
clinical outcomes when stratifying by race (Figure II.A.2).   
Discussion 
          Serum concentrations of PBDEs among women in this cohort decreased over the 
span of the study; they were highest between 2005-2009 and decreased substantially 
from 2010-2015.  There were no consistent associations for PBDEs and metabolites 
with intermediate IVF outcomes.  We observed unexpected positive relationships of 
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BDE153, 3 and 5-OH-BDE47, and 6-OH-BDE47 with clinical IVF outcomes.  Positive 
associations remained for White women in the relationships of BDE153, and 3 and 5-
OH-BDE47 with clinical outcomes.  However, among Other race women, an increase in 
congeners 47, 99, 100, 154 and metabolite 4-OH-BDE49 was associated with a 
decreased probability of clinical IVF outcomes.  Although the study included a very 
small number of Other race women, these results suggest a possible racial disparity in 
PBDE exposure outcome relationships.   
  Serum concentrations of PBDEs in our cohort were higher compared to the 
general population.  From a similar time period (2005-2014), concentrations in our 
cohort of BDE47 (GM=28.1 ng/g lipid), BDE153 (GM=26.3 ng/g lipid), and BDE154 
(GM=7.3 ng/g lipid) were higher than those from pooled samples of women (20-59 
years) from the National Health and Nutrition Examination Survey (NHANES) (GM=21.0 
ng/g lipid, GM=7.9 ng/g lipid, and GM= 0.4 ng/g lipid, respectively) 45.  Concentrations of 
BDE47 among our sample were also nearly double those among pregnant women in 
California (CA) (GM=14.9 ng/g lipid) and North Carolina (NC) (GM=16.5 ng/g lipid) 18,28.  
Of the congeners in our sample, BDE47 is the most abundant in the PentaBDE mixture 
(25-37%) and possibly explains the higher concentrations of BDE47 compared to other 
congeners in our sample 7.  Concentrations of BDE99 (GM=5.5 ng/g lipid) and BDE100 
(GM=5.1 ng/g lipid) in our sample were similar to women in CA (GM=4.4 ng/g lipid and 
GM=2.8 ng/g lipid, respectively) and NC (GM=4.7 ng/g lipid and GM=4.2 ng/g lipid).  
Concentrations of BDE47 among participants of this study (median=24.6 ng/g lipid) 
were nearly five-fold higher compared to women in a different cohort of women seeking 
fertility treatment in Boston between 1994-2003 (median=5.22 ng/g lipid) and nearly 
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three-fold higher among reproductive aged women in Canada (GM=9.0 ng/g lipid) 
between 2007-2009 39,46.  BDE153 concentrations in our sample were also considerably 
higher compared to women in Canada (1.4 ng/g lipid).  Higher PBDE concentrations in 
our cohort could be due to different sampling time periods, as recent serum 
concentrations may be lower due to the phase out compared to samples taken in the 
early 2000s.  Differences in BDE153 levels may also be attributable to changes in diet 
over time and across geographic region.  
 Few studies to date have analyzed PBDE metabolites.  Pregnant women in NC 
had slightly lower concentrations of 6-OH-BDE47 (GM=0.11 ng/g lipid) compared to 
participants of this study (GM=0.19 ng/g lipid) 18.  Concentrations of 4-OH-BDE49 
among our sample were similar (GM=0.20 ng/g lipid) to women in NC (GM=0.17 ng/g 
lipid).  However, among pregnant women in Indiana, concentrations were higher for 5-
OH-BDE47 (median=5.7 ng/g lipid) and 6-OH-BDE47 (GM=1.0 ng/g lipid) compared to 
participants of this study (median<MDL and median=0.18 ng/g lipid, respectively).  Yet 
3-OH-BDE47 (median=0.31 ng/g lipid) and 4-OH-BDE49 (median=0.21 ng/g lipid) were 
higher in our sample compared to women in IN (median=0.4 ng/g lipid and not detected, 
respectively). 
 Concentrations decreased by year of sample collection.   This trend correlates to 
the phase-out of the PentaBDE mixture from US markets in 2004 as BDEs 47, 99, 100, 
and 154 were highest in 2005 47.  A similar trend was also observed for a recent 
decade- long (2005-2014) analysis of pooled PBDE samples from NHANES where 
concentrations for congeners 47, 99, 100, and 154 were lower in recent years for 
people between the ages of  20-59 years 48.  A longitudinal study of pregnant women in 
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CA also observed a steady decrease in congeners 47, 99, 100, and 153 between 2008-
2014 49.   
 Correlations were moderate-to-strong (r=0.30-0.85) among PBDEs, OH-BDEs, 
and between PBDEs and OH-BDEs.  Congeners 47, 99, and 100 had the strongest 
correlations, while congeners 153 and 154 were slightly weaker.  These results were 
expected as congeners 47, 99, and 100 are the most prevalent congeners (by weight) in 
the PentaBDE mixture followed by BDEs 153 and 154 7.  Similar results were observed 
in serum among a sample of 137 pregnant women in NC, where BDE47 was strongly 
correlated to BDE99 (r=0.80) and BDE100 (r=0.80), yet weaker for BDE153 (r=0.52) 18.   
However, among a serum sample of men and women in Shanghai, China (n=25), 
BDE47 was strongly correlated to both BDE100 (r=0.97) and BDE154 (r=0.97) 50.  They 
also observed a strong correlation between BDE100 and BDE154 (r=0.99).  
Correlations for OH-BDEs were slightly weaker among our sample (0.39≤r≤0.59).  
Correlations between 6-OH-BDE47 and 4-OH-BDE49 among pregnant women in NC 
were slightly higher (r=0.62).  All metabolites in this analysis are found in the 
hydroxylation pathway of BDE47, which coincides with our observation of the strongest 
correlations between BDE47 and OH-BDEs (0.47≤r≤0.64) 19.  Similar correlations were 
observed in serum among a sample (n=47) of women in Dalian, China (0.26≤r2 ≤0.65) 
51.   
 Our results for associations of PBDES and OH-BDEs with intermediate IVF 
outcomes were overall null while results with clinical outcomes were positive, though 
unexpected.  An increase in BDE153, 3 and 5-OH-BDE47, and 6-OH-BDE47 was 
associated with an increased probability of implantation, clinical pregnancy, and live 
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birth.  These results are unexpected as prior studies of IVF patients found an increase 
in failed implantation (Odds ratio (OR) =10.0) with detectable BDE153 concentrations in 
follicular fluid (FF) 39.  Another study found increases in BDE100 and BDE153 to be 
associated with a decrease in fecundability odds ratio (fOR) (fOR=0.6 and fOR=0.5, 
respectively) 28.  In all clinical models, metabolites had stronger and positive 
associations with clinical outcomes compared with the parent compound, BDE47.  
These results were unanticipated as previous studies suggest OH-BDEs to be more 
toxic than PBDEs due to their disruption of oxidative phosphorylation, which is 
associated with fertilization and early embryo development 52–54.      
 Although concentrations decreased for PBDEs and OH-BDEs over the study 
period, we did find a slight increase in BDE 47 and 153 along with 3 and 5-OH-BDE47 
and 6-OH-BDE47 concentrations between 2007-2010.  Coinciding with this time period, 
we also observed an increase in the likelihood of successful implantation, clinical 
pregnancy, and live birth rates in our cohort (Figure II.A.4).  Increasing IVF success 
rates over time could have possibly biased our results of PBDEs/OH-BDEs with clinical 
outcomes.  Our results could also be due to residual confounding.  Although we 
adjusted for year of sample collection in our original models and performed a stratified 
analysis based on year (data not shown), it is possible these quantifications of year did 
not appropriately account for the associations for women who underwent multiple cycles 
within the same year compared to their PBDE and OH-BDE concentrations measured at 
study entry.  Seafood consumption possibly mitigated our results with OH-BDEs and 
IVF endpoints as omega-3 polyunsaturated fatty acids (i.e. seafood consumption) have 
been associated with positive IVF outcomes, although results are mixed 55.  A study of 
40 
 
Japanese women found a 20-fold increase in concentrations of 6-OH-BDE47 compared 
to BDE47, likely attributed to seafood consumption 56.      
 When clinical outcomes were stratified by race, on average among Other race 
women the probabilities of implantation, clinical pregnancy, and live birth all decreased 
with increased concentrations of all PBDEs and OH-BDES, except for 6-OH-BDE47.  
However, only the association between BDE47 and a decreased probability of clinical 
pregnancy reached statistical significance, which could be due to the small number of 
Other race women (and cycles) in our sample.  Several studies have established racial 
and ethnic disparities in exposure to endocrine disrupting chemicals, including PBDEs 
among women 57.  We observed higher concentrations of PBDEs among Other race 
women (Figure II.A.3).  Similar results were observed from NHANES, which found 
higher levels of BDE47 and BDE99 among Mexican Americans and Blacks compared to 
Whites 11.  A larger analysis of NHANES data observed higher concentrations of BDE47 
and BDE99 among non-Hispanic Blacks compared to all other race and ethnicity groups 
48.  Higher concentrations of six PBDE congeners have been observed among US Black 
adolescent girls compared to Whites 58.    
 Our study is not without limitations.  Despite the long half-lives of PBDEs ranging 
in the order of years, it is possible for exposure misclassification for women who 
underwent multiple cycles (over months or even years) with only a single exposure 
measurement 59.  Like many other studies, we measured PBDE and OH-BDEs in 
serum, while the measurement of chemicals in FF could potentially be an optimal 
medium for the specific microenvironments for reproductive studies 60,61.  A previous 
IVF study comparing PBDEs in FF and serum detected weak but significant correlations 
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(Kendall’s Tau-beta (Tb) =0.15-0.38) for congeners 47, 100 and 154 39.  We also tested 
associations for multiple congeners and metabolites with multiple outcomes.  Lastly, a 
limitation of the study is that the results were very imprecise for the stratified analyses. 
This could be due to the small sample size among women of Other race (n=30), but 
confidence intervals were also wide for models conducted within White women.  The 
homogeneity of our population, similar to other IVF cohorts, may have resulted in a lack 
of precision of the probabilities of clinical outcomes seen in the Other race stratified 
models 62.  However, we also observed wider confidence intervals for White models.    
 To the best of our knowledge, the present study is the largest prospective 
preconception cohort assessing the association of PBDEs and OH-BDEs on 
reproductive health.  This is also the first study to assess the relationship between 
PBDEs and OH-BDEs with intermediate IVF outcomes (prior to implantation).  An IVF 
cohort also allows for the study of many endpoints critical to a successful pregnancy but 
not observable in a TTP study in the general population.  Our prospective study design 
eliminates the possibility of reverse causation.  Finally, our use of a CWGEE model for 
clinical outcomes account for the multiple cycles per woman and provide more precise 
effect estimates compared to other statistical approaches 43. 
Conclusion 
Among our cohort, PBDEs and OH-BDEs were frequently detected in serum with 
concentrations highest in the early years of the study period, which coincides with the 
phase out of the PentaBDE mixture in 2004 47.  We did not observe any consistent 
trends of PBDEs or OH-BDEs with intermediate IVF outcomes but identified some 
unexpected positive relationships of clinical IVF outcomes with BDE153, 3 and 5-OH-
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BDE, and 6-OH-BDE.  Our stratified models supported prior studies of racial disparities 
with higher concentration of PBDEs among Other race populations.  Future studies 
should focus on the rise in use of alternative FRs as concentrations of PBDEs continue 
to drop as well as employ designs to adequately explore racial or ethnic disparities with 
PBDE exposure and their associations with reproductive health.   
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Table II.1. Demographic and reproductive characteristics for 215 women  
(330 in vitro fertilization cycles) from a subset of the EARTH cohort. 
Characteristics Median or n (IQR or %) 
Demographic (n=215 women)   
Age (years) 35 (32, 38) 
Race/ ethnicity 
     Other race 







Body mass index (kg/m2) 23 (21, 26) 
Ever smoker 60 (28) 
Education 
     High school/some college 
     College graduate 









Reproductive (n=330 cycles)   
Prior pregnancy 78 (36) 
Initial infertility diagnosis 
     Female factor 
     Male factor 









Previous IUI 83 (39) 
Previous IVF 46 (21) 
Day 3 FSH levels a, IU/L  6.8 (6.0, 8.3) 
Treatment protocol 
     Antagonist 
     Flare 









E2 trigger levels b, pmol/L  1998 (1540, 2658) 
Endometrial thickness c (mm)  10 (8.5, 11.2) 
ICSI cycles 164 (52) 
a n=329; b n=317; c n=316; IQR: Interquartile range; Other race: Black/Asian/Other                                                         
BMI: Body mass index; IUI: intrauterine insemination; FSH: Follicle stimulating                                                           




Table II.2. Distribution of unadjusted and lipid-adjusted BDEs and OH-BDEs among 215 women from the EARTH cohort.  
     Percentiles 
BDEs N>MDL (%) GM (95% CI) 25th 50th 75th 95th Max 
Unadjusted (pg/g serum)          
BDE47 175 82.5 12.5 (11.1, 14.2) 6.3 11.1 24.1 70.7 191.2 
BDE99 122 59.2 2.5 (2.2, 2.8) <MDL 2.0 4.5 12.3 67.4 
BDE100 149 71.0 2.3 (2.1, 2.6) <MDL 1.9 3.9 14.3 42.8 
BDE153 201 94.0 12.0 (10.5, 13.8) 6.2 10.3 22.7 80.1 256.5 
BDE154 108 53.1 3.1 (2.8, 3.4) <MDL 3.3 4.8 10.7 26.7 
BDE sum  38.7 (34.9, 42.9) 21.4 34.8 68.0 160.9 287.0 
Lipid-adjusted (ng/g lipid)          
BDE47  28.1 (25.3, 31.3) 13.4 24.6 57.8 145.9 326.5 
BDE99 5.5 (4.9, 6.1) 2.5 5.0 10.6 31.4 162.7 
BDE100 5.1 (4.6, 5.7) 2.3 4.2 10.8 29.9 73.0 
BDE153 26.3 (23.3, 29.7) 13.0 24.5 47.7 172.3 690.3 
BDE154 7.3 (6.7, 7.9) 4.8 7.0 12.2 24.7 62.3 
BDE sum  86.3 (78.6, 94.7) 44.2 78.9 157.8 365.4 758.7 
OH-BDEs          
Unadjusted (pg/g serum)          
3-OH-BDE47 a 76 93.8 0.14 (0.11, 0.19) 0.07 0.12 0.36 0.92 2.0 
3-OH-BDE47 & 5-OH-BDE47 b 132 98.5 0.59 (0.49, 0.72) 0.29 0.60 1.3 3.3 9.9 
5-OH-BDE47 a 1 1.0 0.01 (0.01, 0.01) <MDL <MDL <MDL <MDL 0.81 
6-OH-BDE47 134 62.3 0.09 (0.07, 0.10) <MDL 0.08 0.21 0.96 2.3 
4-OH-BDE49 198 92.0 0.09 (0.08, 0.11) 0.04 0.09 0.18 0.62 1.7 
OH-BDE sum  0.65 (0.56, 0.74) 0.30 0.62 1.3 4.0 10.7 
Lipid-adjusted (ng/g lipid)          
3-OH-BDE47 a  0.32 (0.27, 0.41) 0.13 0.31 0.94 1.8 3.7 
3-OH-BDE47 & 5-OH-BDE47 b 1.3 (1.1, 1.5) 0.64 1.4 2.6 8.1 19.1 
5-OH-BDE47 a 0.02 (0.01, 0.02) <MDL <MDL <MDL <MDL 1.7 
6-OH-BDE47 0.19 (0.17, 0.22) 0.08 0.18 0.45 1.6 4.2 
4-OH-BDE49 0.20 (0.18, 0.23) 0.09 0.21 0.44 1.2 4.1 
OH-BDE sum  0.33 (0.29, 0.37) 0.16 0.35 0.74 2.1 5.6 




Figure II.1. Geometric means of BDEs and OH-BDEs (ng/g lipid) from 215 women    
from the EARTH cohort by year (2005-2015) of sample collection.  (Only one sample 
was collected in 2016 and not included.)  
 
Number of samples per year: 2005: n=4, 2006: n=15, 2007: n=16, 2008: n=35, 2009: n=47, 2010: n=46, 





Figure II.2. Spearman correlation coefficients of BDEs and OH-BDEs (ng/g lipid) among                    




Figure II.3. Adjusted relative risk (RR) (95% CIs) for clinical outcomes among women 
with an interquartile range increase in BDE concentrations (ng/g serum).   
 
Models adjusted for total serum lipid, age, BMI, race (White/Other race), year of BDE sample collection, 




Figure II.4. Adjusted relative risk (RR) (95% CIs) for clinical outcomes among women 
with an interquartile range increase in OH-BDE metabolites concentrations (ng/g 
serum).   
 
Models adjusted for total serum lipid, age, BMI, race (White/Other race), year of BDE/OH-BDE sample 





Chapter II Appendix 
Table II.A.1.  Unadjusted regression coefficients and relative risks (95%) CI for the association of PBDEs (ng/g serum) 
and IVF outcomes from a subset of 215 women (330 IVF cycles) from the EARTH cohort. 
 PBDEs a 
 BDE47 BDE99 BDE100 BDE153 BDE154 BDE Sum 
Intermediate 
outcome b 













-0.08 (-0.22, 0.05) 












-0.04 (-0.17, 0.10) 
Endometrial 
























0.13 (-0.14, 0.40) 
             
Clinical 
outcome e  
RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) 























1.15 (0.70, 1.91) 










1.22 (0.72, 2.06) 
a Natural log transformation; b Generalized linear mixed models; c n=316; d n=314; e Cluster weighted generalized estimating equations; M2:    
Metaphase 2; RR: Risk ratio 
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Table II.A.2.  Regression coefficients and relative risks (95%) CI for the association of PBDEs (ng/g serum) and IVF 
outcomes from a subset of 215 women (330 IVF cycles) from the EARTH cohort. 
 PBDEs a 
 BDE47 BDE99 BDE100 BDE153 BDE154 BDE Sum 
Intermediate 
outcome b 

























































             
Clinical 
outcome e 
RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) 






































a Natural log transformation; b Generalized linear mixed models adjusted for total serum lipid, age, BMI, race (White/Other race), year of BDE 
sample collection, Day 3 FSH levels, IU/L, and IVF protocol (antagonist, flare, luteal phase agonist); c n=316; d n=314; e Cluster weighted 
generalized estimating equations adjusted for total serum lipid, age, BMI, race (White/Other),  year of BDE sample collection, Day 3 FSH levels, 
IU/L, and IVF protocol (antagonist, flare, luteal phase agonist); M2: Metaphase 2; RR: Risk ratio 
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Table II.A.3.  Unadjusted regression coefficients and 95% CI for the association of OH-BDEs and IVF outcomes from a 
subset of 215 women (330 IVF cycles) from the EARTH cohort. 
 OH-BDEs a 
 3-OH47 & 5-OH47  6-OH47 4-OH49 OH-BDE Sum 
Intermediate 
outcome b 
B (95% CI) B (95% CI) B (95% CI) B (95% CI) 
Total oocyte yield c 0.08 (-0.09, 0.25) -0.04 (-0.52, 0.43) -0.01 (-0.58, 0.56) 0.04 (-0.08, 0.15) 
M2 oocyte yield c 0.01 (-0.08, 0.11) -0.01 (-0.22, 0.21) 0.28 (0.04, 0.50) 0.03 (-0.04, 0.10) 
Endometrial wall 
thickness c 
0.21 (-0.25, 0.67) 0.85 (-0.19, 1.89) 0.71 (-0.40, 1.83) 0.26 (-0.07, 0.60) 
Fertilization rate d -0.14 (-0.33, 0.05) 0.19 (-0.24, 0.62) -0.04 (-0.51, 0.43) -0.06 (-0.19, 0.08) 
         
Clinical outcome e RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) 
Implantation 1.71 (1.16, 2.51) 3.07 (1.27, 7.42) 1.92 (0.75, 4.91) 1.57 (1.18, 2.09) 
Clinical Pregnancy 1.72 (1.18, 2.52) 2.68 (1.15, 6.26) 1.65 (0.67, 4.10) 1.54 (1.17, 2.03) 
Live birth 1.52 (1.03, 2.25) 2.86 (1.20, 6.81) 1.83 (0.72, 4.67) 1.47 (1.10, 1.95) 
 
a Natural log transformation; b Generalized linear mixed models; c n=316; d n=314; e Cluster weighted generalized estimating equations; M2:                    




Table II.A.4.  Regression coefficients and 95% CI for the association of OH-BDEs (ng/g serum) and IVF outcomes      
from a subset of 215 women (330 IVF cycles) from the EARTH cohort. 
 OH-BDEs a 
 3-OH47 & 5-OH47  6-OH47 4-OH49 OH-BDE Sum 
Intermediate outcome 
b 
B (95% CI) B (95% CI) B (95% CI) B (95% CI) 


























         
Clinical outcome e RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) 


















a Natural log transformation; b Generalized linear mixed models adjusted for total serum lipid, age, BMI, race (White/Other race), year of             
OH-BDE sample collection, day 3 FSH levels, IU/L, and IVF protocol (Antagonist, Flare, Luteal phase agonist); c n=316; d n=314;                            
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e Cluster weighted generalized estimating equations adjusted for total serum lipid, age, BMI, race (White/Other), year of BDE sample collection, 
Day 3 FSH levels, IU/L, and IVF protocol (antagonist, flare, luteal phase agonist); M2: Metaphase 2; RR: Relative risk.
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Table II.A.5. Relative risk (95% CI) for the association of PBDE and OH-BDEs                
(ng/g serum) and clinical IVF outcomes among 215 women from the EARTH cohort         
stratified by race (White/Other race).   
 Clinical IVF outcomes 
 Implantation Clinical Pregnancy Live Birth 
 RR 95% CI RR 95% CI RR 95% CI 
BDE 
      
BDE47 
   White 




















   White 
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OH-BDEs       
3-OH47 & 5-OH47 
   White 




















   White 




















   White 




















   White 



















Models adjusted for total serum lipid, age, BMI, year of BDE/OH-BDE sample collection, day 3 FSH 
levels, IU/L, and IVF protocol (antagonist, flare, luteal phase agonist).  *Results are presented, however 
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models were unstable and should be interpreted with caution; RR: Relative risk.  Successful implantation: 
White: n= 158, Other race: n= 23, successful clinical pregnancy: White: n= 135, Other race: n= 20, and 
Live Birth: White: n= 108, Other race: n=16)  
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Figure II.A.1. Adjusted relative risk (RR) (95% CIs) for clinical outcomes among women 
with an interquartile range increase in BDE concentrations (ng/g serum) stratified by 
race (Other race: n=43 IVF cycles or White: n=287 cycles).   
 
Models adjusted for total serum lipid, age, BMI, year of BDE sample collection, day 3 FSH levels, IU/L, 




Figure II.A.2. Adjusted relative risks (RR) (95% CIs) for clinical outcomes among women with an interquartile                               
range increase in OH-BDE metabolite concentrations (ng/g serum) stratified by race                                                                     
(Other race: n=43 IVF cycles or White: n=287 cycles).   
 
Models adjusted for total serum lipid, age, BMI, year of BDE/OH-BDE sample collection, day 3 FSH levels, IU/L, and IVF                              
protocol (antagonist, flare, luteal phase agonist).  Results for 6-OH-BDE47 were omitted due to model instability.  RR: Relative risk
64 
 




Figure II.A.4. Clinical IVF outcome success rates from 215 women from the EARTH cohort by year (2005-2015)                                 
of BDE and OH-BDE sample collection.   
 












AIM 2: Reproductive Outcomes Associated with Serum Polybrominated Diphenyl 
Ether and Hydroxylated Brominated Diphenyl Ether Concentrations Among 
Couples Seeking Fertility Treatment: A Paternal Perspective 
Abstract 
Background: Polybrominated diphenyl ethers (PBDEs) have been phased out of 
production for nearly a decade yet are still frequently detected in serum of U.S. adults.  
PBDE concentrations in women have been associated with adverse reproductive 
outcomes and laboratory studies suggest hydroxylated-BDEs (OH-BDEs) may act as 
endocrine disruptors.  However, studies investigating the associations of male PBDE 
and OH-BDE exposure with female partners pregnancy outcomes are lacking.  Our 
study contributes to a limited literature by assessing 1) the joint effects of paternal and 
maternal serum PBDE concentrations on pregnancy outcomes and 2) the association 
between paternal serum OH-BDE concentrations and pregnancy outcomes. 
Methods: This analysis included 189 couples (contributing 285 in vitro fertilization (IVF) 
cycles) recruited between 2006-2016 from a longitudinal cohort based at Massachusetts 
General Hospital Fertility Center who completed at least one IVF cycle and had an 
available blood sample at study entry.  Five PBDE congeners (47, 99, 100, 153, and 
154) and four OH-BDEs (3-OH-BDE47, 5-OH-BDE47, 6-OH-BDE47, and 4-OH-BDE49) 
were quantified in serum.  Log-transformed PBDEs and OH-BDEs were modeled in 
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quartiles for associations with fertilization, implantation, clinical pregnancy, and live birth 
using multivariable generalized mixed models and cluster weighted generalized 
estimating equations while adjusting for male and female lipids, age, body mass index, 
year of serum sample collection, and infertility diagnosis (female, male, unknown).     
Results: Congeners 47, 153, 154, and metabolites 6-OH-BDE47 and 4-OH-BDE49 
were frequently detected (84% >method detection limit (MDL)).  Lipid-adjusted 
concentrations of PBDEs and OH-BDEs were higher in females than in male partners.  
There were no clear patterns of increases in risk of adverse IVF outcomes associated 
with PBDEs and OH-BDEs.  However, some decreases in associations with pregnancy 
outcomes (implantation, clinical pregnancy, and live birth) were observed in isolated 
quartiles; for example, quartile 2 of BDE99 and BD100, and quartile 3 of BDE153. 
Conclusion: Overall, male serum PBDEs or OH-BDES were not associated with 
couples’ reproductive outcomes, although some specific quartiles were associated with 
decreased probabilities of implantation, clinical pregnancy, and live birth.  Our 
assessment of couple level exposure is unique compared to the current literature and 
highlights the importance of including male and female exposures in the assessment of 




     Polybrominated diphenyl ethers (PBDEs) are flame retardants which have been 
phased out of production for nearly a decade, yet concentrations among US adults 
remain high 1.  The most frequently detected congeners (47, 99, 100, 153, and 154) are 
found in (but not exclusively) the PentaBDE commercial mixture, which was primarily 
manufactured in the US until the voluntary phase out at the end of 2004 2,3.  PBDEs are 
not covalently bound but physically combined with materials, which allows them to leach 
into surrounding environments and bioaccumulate in adipose tissues, with half-lives 
ranging from weeks to years 4.  PBDEs were added to consumer products including 
upholstered furniture, carpeting, electronics, and plastics as flame retardants.  In the 
US, PBDE exposure is predominantly from dust due to its common use in these 
products, while diet is a main source of exposure in European countries where it was 
less commonly used 3.  Hydroxylated-BDEs (OH-BDEs), products of oxidative 
metabolism from PBDEs in mammals, also bioaccumulate in humans and have been 
detected in adult serum 5.  Some OH-BDEs are of a natural origin (e.g. biogenic from 
marine sponges) and may contribute to exposure via seafood diets 6.  
     PBDE exposure has been associated with adverse reproductive health outcomes in 
both men and women.  Elevated concentrations of BDE99 and BDE153 in women have 
been associated with failed implantation and longer time to pregnancy (TTP) 7,8.  
Congeners 47, 100, 153, and 154 have also been associated with altered hormone 
levels and poorer semen quality in men, while low-dose in utero exposure to BDE99 in 
mice was associated with poor semen quality in male offspring 9–12.  However, 
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laboratory studies suggest OH-BDEs may act as endocrine disruptors and have greater 
toxic effects compared to PBDEs 13,14.    
     We have previously reported that serum PBDE and OH-BDE concentrations among 
women had unexpected positive associations with implantation, clinical pregnancy, and 
live birth (Ingle, et al. In press).  However, considerations for male exposure with fertility 
and pregnancy outcomes are pivotal in understanding the comprehensive impact of 
PBDE exposure on reproductive health.  This analysis examines the relationship of 
couple (male and female) PBDE and OH-BDE exposures with fertility metrics and 
pregnancy outcomes. 
Methods 
Study Population  
     The male participants (n=189) and their female partners (n=189) included in our 
analysis were a subset of study participants recruited between 2006-2016 from the 
EARTH study, an ongoing longitudinal prospective pre-conception cohort study of the 
environment, dietary, and lifestyle impacts on reproductive health 15.  Men (18-55 years) 
and women (18-46 years) were recruited from Massachusetts General Hospital (MGH) 
Fertility Center.  Approximately 60% of participants contacted by research staff 
participated in the study 16.  Couples (male and female) must have contributed their own 
gametes, completed at least one in vitro fertilization (IVF) cycle (n=285 cycles), and 
provided a blood sample for flame retardant and metabolite quantification.  At study 
entry, research staff collected demographic data and pregnancy history.  Research 
protocols were approved by the Ethics and Research Committees of MGH, Harvard 
T.H. Chan School of Public Health, University of Michigan, and Duke University.  The 
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study was described in detail to participants, all questions were answered, and informed 
consent was obtained from all participants.   
PBDE and OH-BDE Collection and Measurement 
     PBDE and metabolite protocols have been described in detail elsewhere (Ingle, et al. 
In press).  Briefly, 5 mL blood samples collected at study entry were aliquoted, frozen, 
and stored (-80° C) before shipment overnight to Dr. Stapleton’s laboratory at Duke 
University (Durham, NC).  Five PBDE congeners: 47, 99, 100, 153, and 154 and four 
OH-BDE metabolites: 3-OH-BDE47, 5-OH-BDE47, 6-OH-BDE47, and 4-OH-BDE49 
were quantified in serum.   
     Samples were weighed and spiked with internal standards (monofluorinated BDE 69, 
13C BDE 209, and 13C-6-OH-BDE47). Serum was diluted with water and formic acid 
before solid phase extraction (SPE) (Oasis HLB, Waters Corp.).  Dichloromethane 
(DCM) and ethyl acetate (50:50) removed both PBDES and OH-BDEs from the SPE 
column. Samples were dried, rejuvenated with hexane (1 mL) and extract cleaning via a 
1.0 g silica column.  PBDEs were removed with 10 mL of hexane and OH-BDEs with 10 
mL of DCM hexane solution.  PBDEs were analyzed using gas chromatography 
negative chemical ionization mass spectrometry (GC/ECNI-MS) and OH-BDEs were 
measured using liquid chromatography tandem mass spectrometry (LC/MS-MS) 17.  
Accuracy was verified by extracting a human serum Standard Reference Material (SRM 
1957) from the National Institute of Standards and Technology (NIST).  Measured 
values were between 73%- 97% of the certified values.  Total lipids were derived from 
total serum cholesterol and triglycerides using the following formula: TL (g/l) = [ (TC x 
1.12) + (TG x 1.33) + 1.48 where TL= total lipids, TG= serum triglycerides, and TC= 
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serum cholesterol (Covaci et al., 2006).  Missing total lipids (males n=4 and females 
n=13) were replaced with the median (males= 628.6 and females=509.15). 
Clinical Protocols and Outcomes 
     Clinical staff collected participants’ date of birth and measured height and weight to 
calculate body mass index (BMI, kg/m2) at study entry.  At the beginning of each cycle, 
clinical data are abstracted from the female partners’ electronic health records by 
research staff.  Clinical protocols and outcomes have previously been described 18.  
Briefly, initial infertility diagnoses are given by a physician at MGH Fertility Centers in 
accordance with the Society for Assisted Reproductive Technology (SART) definitions 
19,20.  Depending on infertility evaluation and other clinical factors, one of three ovarian 
stimulation protocols was selected: (1) luteal phase gonadotrophin releasing hormone 
(GnRH) agonist, (2) follicular phase GnRH agonist or “flare” stimulation, or (3) GnRH 
antagonist.  Fertilization was confirmed 17-20 hours after IVF or intracytoplasmic sperm 
injection (ICSI) by the presence of an oocyte with two pronuclei.  Fertilization rate was 
defined as the number of two pronuclear embryos divided by the number of metaphase 
II (M2) oocytes.  Successful implantation was confirmed when serum beta human 
chorionic gonadotropin (β-hCG) levels were > 6 mIU/mL, approximately 17 days after 
egg retrieval.  Implantation was characterized as the presence of an intrauterine 
pregnancy confirmed by ultrasound and elevated β-hCG levels (approximately 6 weeks 





     Demographic characteristics for males were characterized using medians together 
with interquartile ranges (IQRs) for continuous variables, and frequencies together with 
percentages for categorical variables.  PBDEs and OH-BDE concentrations below 
method detection limit (MDL) were imputed to MDL/√2 (Hornung and Reed, 1990).  
Unadjusted and lipid-adjusted congeners and metabolites were described using 
geometric means (GM), 95% confidence intervals (CIs), and selected percentiles.  
Spearman correlation coefficients were used to assess relationships between male and 
female serum PBDE and OH-BDE concentrations.  Distributions of congeners and 
metabolites were right-skewed and transformed by the natural logarithm (ln).  
     Concentrations of PBDEs and OH-BDEs were evaluated individually and summed.  
Concentrations were divided into quartiles before inclusion in regression models to 
account for possible non-linear relationships.  The p-value for trend (P-trend) was 
calculated   from a regression model including the median ln-transformed PBDE or OH-
BDE concentration of each quartile.  Associations of congeners and metabolites with 
fertilization rate were evaluated using multivariable generalized linear mixed models 
(binomial distribution and logit function), where a random intercept is introduced to 
account for multiple cycles per couple.  Associations with PBDEs and OH-BDES with 
implantation, clinical pregnancy, and live birth were assessed using cluster weighted 
generalized estimating equation (CWGEE) models, where the weight was the inverse of 
the total number of cycles (cluster size) (Williamson, John et al., 2003).  CWGEE 
models have provided more flexibility to allow for more complex within-cluster 
correlations, and they only need the mean model to be correctly specified.  
Interpretation in CWGEE is at population level, while in contrast, interpretation in 
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generalized linear mixed models is at individual level (23, Ingle, et al. In press).  Due to 
some co-elution with a few batches of 3-OH-BDE47 and 5-OH-BDE47 among female 
samples, male and female metabolites 3-OH-BDE47 and 5-OH-BDE47 were modeled 
as a sum 3&5-OH-BDE47 (Ingle, et al. In press). 
 Demographic covariates considered for final models were male and female: total 
lipids, age and BMI, and male: race (White/Other), education (high school/some college, 
college graduate, graduate degree), smoking status (never/ever) and year of serum 
sample collection.  Reproductive characteristics considered were history of prior 
pregnancy, initial infertility diagnosis (female factor, male factor, or unexplained), 
previous intrauterine insemination (IUI) (yes/no), previous IVF (yes/no), treatment 
protocol (antagonist, flare, or luteal phase agonist), and ICSI (yes/no).  Final covariates 
were included if they were associated with PBDE concentrations in our cohort, 
associated with PBDEs based on prior studies, and known to be a predictor of IVF 
outcomes (Harley et al., 2010b; Johnson et al., 2012).  Analyses were performed using 
SAS 9.4 (SAS Institute Inc., Cary, NC) and R version 3.3.5. P-values < 0.05 were 
considered statistically significant. 
Results 
    Men (n=189) were primarily White (86%), non-smokers (68%) in their mid-thirties 
(median= 36 yrs.) with a BMI typical of the U.S. population (median= 27 kg/m2), and 
they had similar demographic characteristics to a previously reported sample of men 
from the EARTH cohort (Ingle et al., 2018) (Supplemental Table III.A.1).  Almost all men 
(93%) held at least a college degree.  Demographic and reproductive characteristics of 
female partners (n=189) have been described elsewhere (Ingle, et al. In press).  Briefly, 
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female partners were mostly White (86%) with a normal BMI (median=23 kg/m2) in their 
mid-thirties (median=35 years).  Over half of the women (61%) held a graduate degree 
and few reported ever smoking (28%).  The most common infertility diagnosis was male 
factor (36%) followed by unexplained infertility (35%) and female factor (29%).  The 
majority of women underwent luteal phase agonist protocol (69%), followed by flare 
(18%), and antagonist (13%).  Over half of fertilization was via ICSI (52%). 
 Descriptive statistics of unadjusted and lipid-adjusted male PBDEs and OH-
BDEs are presented in Table III.1.  Congeners 47, 153, and 154 were frequently 
detected (88% >MDL).  Concentrations of BDE47 (GM=12.8 ng/g serum) and BDE153 
(GM=14.5 ng/g serum) were over 4-fold higher than BDE99 (GM=2.2 ng/g serum) and 
BDE100 (GM=2.6 ng/g serum).  Metabolites 3-OH-BDE47 and 4-OH-BDE49 were also 
frequently detected in men (84%>MDL).  Median concentrations of 3-OH-BDE47 (0.14 
ng/g serum) were more than double those of 6-OH-BDE47 (median=0.06 ng/g serum).  
Female partners’ distributions of serum PBDE and OH-BDE concentrations have 
previously been described (Ingle, et al. In press).  Briefly, PBDEs 47, 100, 153, and 
metabolites 3-OH-BDE47, and 4-OH-BDE49 were frequently detected (70%>MDL) and 
concentrations of BDE47 and BDE153 were approximately 5-fold higher than BDE99 
and BDE100.  Median concentrations of 3-OH-BDE47 (0.12 ng/g serum) in women 
were slightly higher than 4-OH-BDE49 (median=0.09 ng/g serum) concentrations.  The 
median of lipid-adjusted concentrations of all congeners were higher in female partners 
compared to males (p<0.001) (Figure III.1).  Lipid adjusted median concentrations of 
BDE47 (24.6 ng/g lipid) and BDE153 (24.5 ng/g lipid) were almost 3-fold higher among 
female partners compared to males (8.1 and 7.7 ng/g lipid).  OH-BDE concentrations 
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were also higher in female partners compared to males (p<0.001) (Supplemental Figure 
III.A.1).  Median concentrations of 4-OH-BDE49 (0.21 ng/g lipid) and 6-OH-BDE47 (0.18 
ng/g lipid) were nearly three and four times (respectively) higher among female partners 
compared to men (0.07 and 0.04 ng/g lipid) (Supplemental Figure III.A.1).   
      Correlations of serum PBDEs and OH-BDEs for male and female partners are 
presented in Figure III.2.  Among men, correlations for congeners 47, 99, and 100 were 
the strongest (r: 0.84-0.85).  Correlations for BDE153 and BDE154 were slightly weaker 
(r: 0.38-0.54), yet still statistically significant.  Metabolites 6-OH-BDE47 and 4-OH-
BDE49 were strongly correlated (r=0.64).  The combined metabolite 3&5-OH-BDE47 
was moderately correlated with BDEs 47, 99, and 100 (r: 0.51-0.61).  A detailed 
description of PBDE and OH-BDE correlations among female partners has been 
described elsewhere (Ingle, et al. In press).  Correlations for PBDES between females 
and males were strongest for BDE47 (r=0.47) and weakest for BDE153 (r=0.24). 
Correlations for OH-BDEs between males and their female partners were weak (r: 0.22-
0.34) but statistically significant, except for the association of female 3&5-OH-BDE47 
and male 6-OH-BDE47 (p>0.05). PBDE and OH-BDE concentrations among men 
declined between 2006 and 2007 and remained consistent throughout the study (Figure 
III.3).  The largest decline was observed for BDE47 which decreased 84% between 
2006-2007.  Metabolite concentrations fluctuated, yet generally declined over the study 
period.   
     No associations were observed between any PBDEs or OH-BDEs and fertilization 
rate (Tables III.A.2 and III.A.3).  However, some of the quartiles, specifically quartile 2 
(Q2) or Q3 were associated with poorer IVF outcomes.  For instance, a 38% decrease 
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in the probability of implantation (Relative risk (RR)=0.62; 95% CI: 0.45, 0.84; p=0.002), 
39% decrease in probability of clinical pregnancy (RR=0.61; 95% CI: 0.42, 0.86; 
p=0.01), and 36% decrease in the probability of live birth (RR=0.64; 95% CI: 0.44, 0.91; 
p=0.02) was observed among female partners of men in Q2 of serum BDE99 
concentrations compared to Q1 (reference group) (Figure III.4).  Similarly, a decrease in 
the probability of implantation, clinical pregnancy, and live birth was found among 
female partners of men in Q2 of serum BDE100 concentrations compared to Q1 
(RR=0.62; 95% CI: 0.45, 0.86; p=0.004, RR=0.59; 95% CI: 0.41, 0.84, p=0.004, and 
RR=0.56; 95% CI: 0.37, 0.87; p=0.01, respectively).  On the other hand, Q3 serum 
concentrations of BDE153 were associated with a 37% decrease in the probability of 
implantation (RR=0.63; 95% CI: 0.46, 0.86; p=0.004), 34% decrease in the probability of 
clinical pregnancy (RR=0.64; 95% CI: 0.47, 0.92; p=0.02), and 38% decrease in the 
probability of live birth (RR=0.62; 95% CI: 0.40, 0.96; p=0.03) compared to men in Q1 
group of exposure.  A 37% increase in the probability of implantation was observed for 
female partners of men in Q2 of serum BDE154 concentrations compared to men in Q1 
(RR=0.63; 95% CI: 1.01, 1.82; p=0.04).  Summed serum OH-BDE concentrations in Q2 
and Q4 among males were associated with an increase in the probability of live birth for 
female partners (RR=2.17; 95% CI: 1.34, 3.53; p=0.001 and RR=2.12; 95% CI: 1.29, 
3.49; p=0.003; p-trend=0.03, respectively) compared to men with summed serum 
concentrations in Q1 (Figure III.5). 
Discussion 
     This study investigated associations of paternal serum concentrations of PBDEs and 
OH-BDEs with couples’ pregnancy outcomes while accounting for female exposure.  
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While we found overall no significant associations, we also observed decreased 
probabilities of successful implantation, clinical pregnancy, and live birth among female 
partners of men in Q2 of serum BDE99 and BDE100 concentrations, and Q3 
concentrations of BDE153, compared to men in Q1.  These non-linear relationships 
were unexpected, and possibly spurious, yet biologically plausible if PBDEs are acting 
as endocrine disruptors which have been associated with unconventional dose-
response relationships 24,25.  For instance, non-linear dose-response relationships have 
been observed between congeners 99, 100, and 153 thyroid stimulating hormone levels 
during pregnancy 26. 
       Several studies have observed negative associations between sperm count, 
concentration, and morphology and BDE153 in men, while low doses of BDE99 in mice 
have been associated with decreased sperm and spermatid counts 9,11,27,28 .  Other 
studies suggest PBDEs act as an endocrine disruptor and alter male reproductive 
hormones.  Congeners 47 and 99 have been inversely associated with inhibin B and 
positively associated with follicular stimulating hormone (FSH) and lower levels of 
inhibin B and higher levels of FSH are often observed in subfertile men 12.  Reported 
associations between PBDEs and thyroid functions is inconsistent 29–31.  However, both 
hypo and hyperthyroidism have been associated with male infertility 32,33. 
     To the best of our knowledge, only one prior study has assessed the relationship of 
serum PBDE concentrations among couples with TTP and we are the first to evaluate 
pregnancy outcomes from conception to live birth.  A prior study of 501 couples found 
no associations with the pentaBDEs and TTP yet did observe a 14% decrease in 
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fecundability odds ratio (FOR) with elevated male serum BDE183 concentrations 34.  
However, there was no adjustment for female concentrations or covariates.   
     Couple comparison studies of PBDEs and OH-BDEs are limited.  However, adjusted 
GMs for PBDEs were significantly higher overall in males compared to females in a 
pooled sample from the National Health and Nutrition Examinations Survey (NHANES) 
1.  Correlations for BDE153 were the weakest among our couples (r=0.24) and possibly 
a result of exposure through diet which can vary by individual 35,36.  Differences among 
couples could also be a result of separate ‘workday’ microenvironments.  In a sample of 
20 homes in Boston, MA, congeners from the PentaBDE mixture were 72% higher in 
the main living area compared to the bedroom 37.  Lower PentaBDE dust concentrations 
have also been observed in recently constructed buildings compared to older buildings 
in the Boston area 38.   
     However, we observed more comparable distributions among women and their 
partners for unadjusted PBDE and OH-BDE concentrations and therefore serum lipid 
levels may be driving the difference in lipid-adjusted concentrations.  We observed 
statically higher total serum lipids and BMIs in men compared to women (Figure III.A.2).  
PBDEs bioaccumulate in adipose tissue and restrict exposure to vital organs, however 
adipose storage and lipid metabolism varies by sex 39.  Therefore, it is possible that 
lipid-adjusted concentrations were higher in females due to sex differences in lipid 
metabolism and fat storage.  However, differences in PBDE concentrations could be 
attributed to BMI as an inverse association was also observed for congeners 47 and 
153 with BMI among a sample of women from CA 41.  A laboratory study also observed 
impaired glucose homeostasis in lean mice undergoing IVF compared to obese mice 
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exposed to polychlorinated biphenyls (PCBs) through diet 40.   Therefore, it is also 
possible that IVF alters the rate at which lipids are metabolized and results in increased 
PBDE concentrations circulating throughout females.   
     Serum concentrations of congeners 47, 99, 100, and 153 among our men are similar 
to those seen in another male cohort (n=50) in Boston 42.  As far as we are aware, we 
are the first study to describe OH-BDEs among adult men in the US.  Comparisons of 
PBDE and OH-BDE concentrations of our female partners with other studies has been 
described elsewhere (Ingle, et al., In press). Briefly, PBDE concentrations were higher 
in our female partners compared to women in other cohorts.  Concentrations of BDE47 
among our sample were approximately double those from women in California and 
North Carolina, yet similar for BDE99 7,17.  BDE153 concentrations among our female 
partners were also higher compared to a sample of women in Canada 44.   
Concentrations of 6-OH-BDE47 were higher compared to pregnant women in NC, yet 
lower than pregnant women in IN 5,17.  Concentrations of 3-OH-BDE47 and 4-OH-
BDE49 were higher in our female partners compared to pregnant women in IN.  Higher 
concentrations among our women could possibly be a result of rapid lipid peroxidation 
in women undergoing IVF compared to women in the general population which would 
result in the release of chemicals stored in adipose tissues. 45.       
     Detection rates were high for BDEs: 47, 153, and 154 and OH-BDEs 3-OH-BDE47 
and 4-OH-BDE49 (84% >MDL) in males, yet concentrations subtly declined over the 10-
year study period.  We observed the largest decrease in serum PBDE concentrations 
between 2006-2007 which is inconsistent with a previous EARTH study as well as 
cohorts in California which observed substantial declines in concentrations over time 
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(46,Ingle, et al., In press).  Such a drastic decrease in the early years of the study was 
likely a result of the phase-out of PBDEs.  Although the PentaBDE phase-out was not 
mandatory until 2005, many manufacturers voluntarily began to restrict these 
compounds a few years prior.   
      Although we observed statistically significant associations with several congeners 
and pregnancy outcomes for some exposure quartiles, a larger sample size would 
increase study power.  Type l error is also plausible as we compared many congeners 
and metabolites with many outcomes.  While IVF cohorts may not be as generalizable 
compared to TTP studies, our results are generalizable to other subfertile cohorts and 
possibly the general population if the biological response to PBDEs is similar for both 
IVF and non-IVF patients.  Nevertheless, our cohort of IVF couples represents a 
susceptible population.  Prospective pre-conception studies allow for the highlighting of 
specific critical windows during conception and gestation 46.  Our study design expands 
upon other pre-conception cohorts by measuring early developmental and clinical 
endpoints which are not observable in studies of the general population.  However, if 
PBDEs and OH-BDES do elicit responses through endocrine disruption, the addition of 
a reproductive hormone analysis could establish a biological relationship between 
PBDEs and OH-BDEs with pregnancy outcomes.  Although typically a homogeneous 
population, IVF patients are highly motivated and require multiple office visits which 
maximize participant retention rate.  Finally, infertility is a couple-based disease, and 
inclusion of couples allows for a more comprehensive assessment of the impact of 




     Despite a decade long phase-out, PBDEs were still widely detected and serum 
concentrations of PBDEs, on a lipid adjusted basis, were significantly higher in female 
compared to male partners.  Overall, we did not observe any associations between 
male serum PBDEs or OH-BDEs and pregnancy outcomes, although some specific 
quartiles were associated with decreased probabilities of implantation, clinical 
pregnancy, and liver birth.  Our assessment of couple level exposure is unique 
compared to the current literature and highlights the importance of including male and 
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Table III.1. Distribution of unadjusted and lipid adjusted PBDEs and OH-BDEs among 189 men from the EARTH cohort.  
     Percentiles 
PBDEs N>MDL (%) GM (95% CI) 25th 50th 75th 95th Max 
Unadjusted (pg/g serum)          
BDE47 166 87.8 12.8 (11.0, 15.0) 5.7 12.1 25.5 103.2 374.3 
BDE99 109 57.7 2.2 (1.9, 2.5) <MDL 1.6 3.7 14.7 37.8 
BDE100 112 59.3 2.6 (2.3, 3.0) <MDL 2.0 4.6 14.6 78.9 
BDE153 181 95.8 14.4 (12.2, 16.9) 6.5 10.8 26.8 146.1 768.0 
BDE154 196 96.3 3.7 (3.2, 4.1) 2.2 3.7 6.3 14.3 32.8 
Total BDEs  43.6 (38.2, 49.8) 22.6 36.8 74.6 238.4 808.0 
Lipid Adjusted (ng/g lipid)          
BDE47   8.8 (7.1, 9.9) 3.5 8.1 17.7 60.7 224.5 
BDE99   1.4 (1.2, 1.6) 0.79 1.1 2.4 8.9 46.1 
BDE100   1.7 (1.5, 2.0) 0.96 1.3 3.1 9.2 47.3 
BDE153   9.4 (7.9, 11.1) 4.2 7.7 18.1 94.0 530.7 
BDE154   2.4 (2.1, 2.7) 1.3 2.4 4.3 12.1 18.9 
Total BDEs   28.5 (24.8, 32.9) 14.5 25.4 47.1 150.0 558.4 
OH-BDEs          
Unadjusted (pg/g serum)          
3-OH-BDE47 159 84.1 0.15 (0.13, 0.17) 0.09 0.14 0.27 0.74 1.3 
5-OH-BDE-47 13 4.6 0.02 (0.02, 0.02) 0.01 0.02 0.02 0.03 0.46 
6-OH-BDE47 107 56.6 0.07 (0.06, 0.08) <MDL 0.06 0.18 1.03 2.3 
4-OH-BDE49 166 87.8 0.10 (0.08, 0.12) 0.04 0.10 0.24 1.1 2.1 
Total OH-BDEs  0.40 (0.35, 0.46) 0.19 0.34 0.73 2.2 4.4 
Lipid-Adjusted (ng/g lipid)          
3-OH-BDE47   0.10 (0.08, 0.11) 0.05 0.09 0.17 0.51 1.8 
5’OH-BDE-47   0.01 (0.01, 0.01) 0.01 0.01 0.02 0.03 0.39 
6’OH-BDE47   0.05 (0.04, 0.06) 0.02 0.04 0.12 0.66 1.6 
4’OH-BDE49   0.07 (0.05, 0.08) 0.02 0.07 0.17 0.75 1.6 
Total OH-BDEs   0.26 (0.23, 0.30) 0.12 0.23 0.54 1.5 3.4 
 
MDL: Method detection limit; GM: Geometric mean; CI: Confidence interval 
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Figure III.1. Distributions of serum PBDEs concentrations (ng/g lipid) among 189 





Figure III.2. Spearman correlation coefficients for serum concentrations of PBDEs and 








Figure III.3. Geometric means of serum PBDE and OH-BDE concentrations among 189 
men from the EARTH cohort by year. 
 
2006: n=2; 2007: n=5; 2008: n=26; 2009: n=44; 2010: n=45; 2011: n=48; 2012: n=38; 2013: n=36; 2014: 










Figure III.4. Relative risk (95% CI) of clinical IVF outcomes by quartile of serum PBDE 




Cluster weighted generalized estimating equations adjusted for female serum PBDE concentrations, male 
and female serum lipids, male and female age, male and female BMI, year of serum sample collection, 
and infertility diagnosis (female, male, unknown);  P-value for trend (P-trend) was calculated as the 
median ln-transformed PBDE concentration of each quartile; RR: Relative risk; CI: Confidence interval; * 







Figure III.5. Relative risk (95% C) of clinical IVF outcomes by quartile of serum OH-




Cluster weighted generalized estimating equations adjusted for female serum OH-BDE concentration, 
paternal and maternal lipids, paternal and maternal age, paternal BMI, year of serum sample collection, 
and infertility diagnosis (female, male, unknown); The p-value for trend (P-trend) was calculated as the 
median ln-transformed serum OH-BDE concentration of each quartile; RR: Relative risk; CI: Confidence 
interval;  * Quartile is statistically different (p<0.05) from Q1 (reference)
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     Chapter III Appendix 
Table III.A.1. Demographic characteristics for 189 men from the EARTH                                      
cohort. 
Characteristics Median or n (IQR or %) 
   
Age (years) 36 (33, 40) 
Race/ ethnicity  
     Black/Asian/Other 







Body mass index (kg/m2) 27 (24, 29) 
Ever smoker 59 (32) 
Education 
     High school/some college 
     College graduate 













Table III.A.2. Regression coefficients (95% CI) of fertilization rate by quartile of serum                                                                                         
PBDE concentrations among 189 men (285 IVF cycles) from the EARTH cohort. 
 Fertilization Rate 
 Unadjusted Models Adjusted Models a 

















































































































































































































p-trend 0.65 0.72 
a Models adjusted for adjusted for female serum PBDE concentrations, male and female serum lipids,                                                                                                        
male and female age, male and female BMI, year of serum sample collection, and infertility diagnosis                                                                                                     
(female, male, unknown); P-trend was calculated as the median ln-transformed serum PBDE 




Table III.A.3. Regression coefficients (95% C) of fertilization rate by quartile of serum                                                     
OH-BDE concentrations among 189 men (285 IVF cycles) from the EARTH cohort. 
 Fertilization Rate 
 Unadjusted Models Adjusted Models a 













































































































































p-trend 0.65 0.28 
a Models adjusted for adjusted for female serum OH-BDE concentrations, male and female serum lipids,                                                                                                        
male and female age, male and female BMI, year of serum sample collection, and infertility diagnosis                                                                                                     
(female, male, unknown); The p-value for trend (P-trend) was calculated as the median ln-transformed 




Table III.A.4. Unadjusted relative risk (95% C) of clinical IVF outcomes by quartile of 
serum PBDE concentrations among 189 men (285 IVF cycles) from the EARTH cohort. 
 Clinical IVF Outcomes 
 Implantation Clinical  Live Birth 
BDE RR (95% CI) p-
value 
RR (95% CI) p-
value 























































































































































































































































































































p-trend 0.55 0.64 0.95 
Cluster weighted generalized estimating equations; The p-value for trend (P-trend) was calculated as the 
median ln-transformed serum PBDE concentration of each quartile; RR: Relative risk; CI: Confidence 





Table III.A.5. Unadjusted relative risk (95% C) of clinical IVF outcomes by quartile of 
serum OH-BDE concentrations among 189 men (285 IVF cycles) from the EARTH 
cohort. 
 Clinical IVF Outcomes 
 Implantation Clinical  Live Birth 
OH-BDE RR (95% CI) p-
value 
RR (95% CI) p-
value 










































































































































































































p-trend 0.15 0.32 0.07 
Cluster weighted generalized estimating equations; The p-value for trend (P-trend) was calculated as the 
median ln-transformed serum OH-BDE concentration of each quartile; RR: Relative risk; CI: Confidence 












Table III.A.6. Relative risk (95% C) of clinical IVF outcomes by quartile of serum PBDE 
concentrations among 189 men (285 IVF cycles) from the EARTH cohort. 
 
 Clinical IVF Outcomes 
 Implantation Clinical  Live Birth 
BDE RR (95% CI) p-
value 
RR (95% CI) p-
value 



















































































































































































































































































































p-trend 0.84 0.29 0.66 
Cluster weighted generalized estimating equations adjusted for female serum PBDE concentrations, male 
and female serum lipids, male and female age, and male and female BMI, year of serum sample 
collection, and infertility diagnosis (female, male, unknown);  The p-value for trend (P-trend) was 
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calculated as the median ln-transformed serum PBDE concentration of each quartile; RR: Relative risk; 




Table III.A.7. Relative risk (95% C) of clinical IVF outcomes by quartile of serum OH-BDE                                                         
concentrations among 189 men (285 IVF cycles) from the EARTH cohort. 
 
 Clinical IVF Outcomes 
 Implantation Clinical  Live Birth 












































































































































































































p-trend 0.23 0.34 0.03 
Cluster weighted generalized estimating equations adjusted for female serum OH-BDE concentrations, male and female serum                                                          
lipids, male and female age, male and female BMI, year of serum sample collection, and infertility diagnosis                                                                                   
(female, male, unknown); The p-value fore trend (P-trend )was calculated as the median ln-transformed serum OH-BDE concentration                  
of each quartile; RR: Relative risk; CI: Confidence interval; REF: Reference quartile; p-values <0.05 are in bold.  
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Figure III.A.2. Distributions of total serum lipids and BMI (kg/m2) among 189 couples 















AIM 3 Part A:  The association of Urinary Organophosphate Ester Metabolites and 
self-Reported Personal Care and Household Product Use Among Couples 
Seeking Fertility Treatment   
 
Abstract  
Background: Organophosphate esters (OPEs) are widely detected.  They are used 
both as flame retardants as well as plasticizers.  
Methods:  230 women and 229 men, a subset of a larger cohort, were recruited from 
Massachusetts General Hospital fertility clinic between 2005 and 2015.  At each visit, 
participants completed a questionnaire of personal care product (PCP) and household 
product (HP) use.  Metabolites [bis(1,3-dichloro-2-propyl) phosphate, diphenyl 
phosphate (DPHP), isopropylphenyl phenyl phosphate (ip-PPP), tert-butylphenyl phenyl 
phosphate and bis(1-chloro-2-propyl) phosphate] were measured in urine (1-5 samples; 
n=638 women, n=335 men).  Associations were assessed using generalized mixed 
models, adjusted for specific gravity, age, BMI, smoking, education and season. 
Results: In women, moisturizer (60%), nail polish remover (77%) and nail polish (134%) 
use were associated (p<0.05) with an increase in DPHP concentrations, while ip-PPP 
concentrations increased 21-27% with conditioner, cosmetics, deodorant and hair 
product use.  Mouthwash and vinyl glove use were associated with a respective 31 and 
92% increase in DPHP among men. 
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Conclusions: Our exploratory analysis suggests OPEs used as a plasticizer in 
consumer products, and nail polish use contributes to internal DPHP exposure.  Further 
research is needed to understand how OPEs are used in these products and how it 




Organophosphate esters (OPEs) have been used as flame retardants (FR) for 
over 150 years 1,2.  The use of  OPEs has grown drastically since the phase out of 
polybrominated diphenyl ethers (PBDEs) in the past decade due to concerns regarding 
their persistence and toxicity 3–5.  As their prevalence rose, OPEs evolved into a high 
production volume chemical with US production projected to reach approximately 
50,000 tons per year by 2020 for certain compounds 6.  OPEs include both chlorinated 
alkyl esters such as tris(2-chloroisopropyl) phosphate (TCIPP) and tris(1,3-
dichloroisopropyl) phosphate (TDCIPP), and non-halogenated aryl phosphates such as 
triphenyl phosphate (TPHP) and isopropyl triphenyl phosphate (ITP) 7.  TPHP and ITP 
account for 60% of Firemaster® 550, a widely used commercial flame retardant mixture 
that replaced PBDEs in furniture foams and baby products, yet are also used as a 
plasticizer in paints, lacquers, and varnishes 8–11.     
 Considered ‘additive’ compounds, OPEs are physically added or ‘mixed’  with 
materials during manufacturing, rather than being chemically bound 10,12.  The main 
route of exposure of OPEs was thought to be dust ingestion as a result of the weak 
bonds allowing for volatilization and settlement into dust of indoor environments 13,14.  
However, recent studies using air samplers, hand wipes and silicone wrist bands have 
shown that inhalation and dermal exposure may also be pathways of exposure  6,11,15.  
Despite the short biological half-lives ranging from a few hours to days, metabolites of 
OPEs have been detected in nearly 100% of urine samples among women, men, and 
children in the US and Europe 14,16–19.  Despite being rapidly metabolized once in the 
body, high detection of OPEs suggests exposure is continuous and widespread.  
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Research on the health effects of OPEs is limited, although prior studies have shown 
adverse immunologic and neurologic outcomes, as well as associations with the 
disruption of endocrine, reproductive, and developmental systems 20–24.  As of 2011, 
TDCIPP and tris(2-chloroethyl) phosphate (TCEP) are listed as a known carcinogens by 
the state of California 25. 
 These compounds have been highly detected in environmental samples, and 
primary sources are thought to be polyurethane foams found in furniture, baby products, 
and electronics 26–28 .  Few studies to date have assessed the prevalence of OPEs in 
other consumer products and personal care products (PCPs) where they may be 
utilized as a plasticizer.  A widely used OPE, TPHP is commonly listed as an ingredient 
in nail polishes.  Several studies have also detected TPHP in products where it was not 
listed as an ingredient 29–31.  A small study found urine concentrations of diphenyl 
phosphate (DPHP), a metabolite of TPHP, to increase 7-fold after nail polish application 
30.  Our present work expands upon this preliminary evidence to characterize the 
relationship between self-reported PCP and household product (HP) use within 24 
hours of a urine sample measuring the concentration of five OPE metabolites: bis(1-
chloro-2-propyl) phosphate (BCIPP), bis(1,3-dichloro-2-propyl) phosphate (BDCIPP), 
DPHP, isopropylphenyl phenyl phosphate (ip-PPP), tert-butylphenyl phenyl phosphate 
(tb-PPP) among couples attending a fertility clinic. 
Materials and Methods 
Participant Recruitment 
Couples from this analysis are a subset from the EARTH study, an existing 
prospective cohort assessing the impact of environmental agents on reproductive 
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health.  Recruitment and participation have been previously described 23,32.  Briefly, 
women (18-46 yrs.) and men (18-55 yrs.) were recruited from Massachusetts General 
Hospital (MGH) Fertility Center between 2005-2015.  Among couples approached for 
the EARTH study, approximately 60% of women and 50% of men agreed to participate.  
Women were included in this analysis if they provided at least one urine sample for 
OPE measurement and completed the PCP and HP questionnaire during an in vitro 
fertilization cycle, while men must have provided at least one urine sample for OPE 
measurement, completed the questionnaire, and have a woman partner also in the 
study 33.  Men were excluded only if they had a prior vasectomy.  Informed consent was 
given by each participant and Institutional Review Board approval was received by all 
institutions. 
Personal Care Product (PCP) and Household Product (HP) Questionnaires 
At the time of enrollment, couples completed questionnaires capturing 
demographic, health history, and lifestyle factors.  At the beginning of each subsequent 
visit, women and men completed a questionnaire on PCP (n=20 products) and HP 
(n=14 products) use within the last 24 hrs.  Consumer products with n<5 participants 
reporting use in the last 24 hrs. was excluded from the analysis.  
Urine Collection and Phosphorous-Containing Flame Retardant Analysis 
One urine sample (up to five samples per participant) were collected in sterile 
polypropylene cups from couples at each visit.  After collection, specific gravity (SG) 
was measured for each sample using a Protometer handheld 100B refractometer 
(National Instrument Company, Inc., Austin, TX).  Samples were then separated into 
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aliquots and frozen (-80°) prior to overnight shipment on dry ice to H.M. Stapleton’s 
laboratory at Duke University (Durham, NC) for analysis. 
 Extraction and analysis of OPE metabolites BCIPP, BDCIPP, DPHP, ip-PPP, and 
tb-PPP have been established and previously described 34.  Briefly, samples were 
thawed and separated into glass tubes in 5 mL aliquots and spiked with internal 
standards (d10-BDCIPP = 80 ng, d10-DPHP = 60 ng).  Samples were then acidified to pH 
<6.5 with formic acid and diluted 1:1 with water.  Samples were concentrated and 
cleaned using solid phase extraction (SPE) before nitrogen stream drying and then 
spiked with recovery standard (13C2-DPHP = 81.5 ng).  Extracts were analyzed using 
negative electrospray ionization liquid chromatography tandem mass spectrometry (LC-
MS/MS).  Data were acquired using optimal parameters under multiple reaction 
conditions.  Internal standard used for BCIPP and BDCIPP was d10-BDCIPP, while 
DPHP, ip-DPHP, and tb-PPP were quantified using d10-DPHP.  Urinary SG ranged from 
1.002-1.100 (geometric mean (GM)=1.104) for women and 1.011-1.038 (GM=1.017) for 
men. 
 Procedures for quality control and assurance for LC-MS/MS have been 
previously reported 23.  Samples were analyzed in 10 separate batches including five 
blanks (5 mL Mili-Q water) to establish a distinct method detection limit (MDL) for each 
batch.  Laboratory blanks were multiplied three times the standard deviation to establish 
MDLs which ranged from: 0.07-0.17 pg/mL for BCIPP, 0.02-0.11 pg/mL for BDCIPP, 
0.09-0.18 pg/mL for DPHP, 0.06-0.12 pg/mL for ip-PPP, and 0.04-0.15 pg/mL for tb-
PPP.  A standard reference material (SRM) was established using pooled samples from 




Distributions of OPEs have been previously reported for participants 23,35.  Due to 
the low frequency of detectable concentrations, BCIPP was henceforth excluded in this 
analysis.  Metabolite concentrations below MDL were imputed as MDL/√2.  An 
aggregate variable (∑OPE) was imputed by summing the molar urinary concentrations 
for metabolites BDCIPP, DPHP, and ip-PPP.  Spearman correlation coefficients were 
calculated for each metabolite among 229 couples.  Metabolites BDCIPP, DPHP, ip-
PPP, and ∑OPE presented as right-skewed and were therefore transformed by the 
natural logarithm for further statistical modeling.     
 Questionnaire responses to PCP and HP use within the last 24 hours was 
evaluated as binary (‘yes’ or ‘no’) where those who responded ‘don’t know’ (n<9 per 
consumer product) were re-coded as a ‘no’ response.  OPE metabolites were evaluated 
as continuous variables except for tb-PPP, which had low detection rates (13.32% for 
women and 11.34% for men) and was modeled as detect/non-detect (data not shown).  
Covariates for modeling were selected a priori and through bivariate testing (data not 
shown) 32,36,37.  Final models were adjusted for SG, age, BMI, race (other/Caucasian) 
smoking (never/ever), education (high school, some college/college, or 
graduate/graduate degree), and season (winter/spring/summer/fall).  Models that 
included year of collection had decreased goodness of fit and are not presented.   
Missing covariates were imputed with the median for continuous variables (age=34 for 
women, n= 16 and BMI=26.84 for men, n=3) and the category with the highest 
frequency (education=graduate degree, n=61 women and n=38 men).  Multivariable 
generalized mixed models were used to evaluate associations with repeated PCP and 
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HP use (exposure) and OPE metabolite concentrations (outcome) using a normal 
distribution with identity link (Supplemental Tables IV.1-4).  Regression coefficients and 
95% confidence intervals (CI) were transformed to reflect the adjusted percent change 
in urinary OPE metabolite concentrations with reported use of each PCP and HP within 
24 hrs. of urine sample (Supplemental Tables IV.5-8).  Heat maps were then generated 
to graphically display the adjusted percent change (Figures IV.1-4; statistical 
significance is indicated by an asterisks on maps).  A sensitivity analysis dividing 
observations into five year increments (2005-2009 and 2010-2015) was conducted to 
investigate possible changes in consumer product formulations by time period (data not 
shown).  All statistical analyses were carried out using SAS 9.4 (SAS Institute Inc., 
Cary, NC).   
Results 
Our subset from the EARTH cohort consisted of 230 women and 229 men 
contributing one to five urine samples per participant (n=638 women and n=335 men).  
Demographic characteristics of these women and men have been previously reported 
23,35.  Briefly, this sample consisted primarily of Caucasian (87%), non-smoking (75%), 
and highly educated (57% hold graduate degree) women with an average age of 35 23.  
Men were slightly older than women (Mean=36.78 yrs.), yet also predominantly White 
(89%), non-smokers (70%) with 82% holding a college degree or higher 35. 
 Self-reported PCP use for women and men within 24 hrs. of urine sample 
collection are depicted in Table IV.1.  The most commonly used PCPs by women were 
deodorant (n=378), shampoo (n=367), toothpaste (n=364), conditioner/cream rinse 
(n=323), and bar soap (n=321).  Suntan/sun block lotion (n=49), nail polish remover 
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(n=23), and nail polish (n=21) had the lowest reported use.  Similarly, men also 
frequently reported using deodorant (n=211), shampoo (n=204), toothpaste (n=190), 
and bar soap (n=177), but also shaving cream (n=87).  Less frequently reported PCPs 
among men included aftershave, other hair products, and suntan/sunblock lotion 
(<10%).  Reported HP use was less frequent among women and men compared to PCP 
(Table IV.2).  However, both women and men reported use of laundry detergent, hand 
dishwashing liquid and cleaners.  For women, vinyl gloves, furniture polish, and vinyl 
boots were less frequently used (<6%), while vinyl gloves, fabric softener, and 
paint/solvents were the least reported HP for men (<5%). 
 Metabolites BDCIPP, DPHP, and ip-PPP were highly detected among both 
women (85%, 90%, and 75%) and men (85%, 86%, and 67%)  23,35.  Metabolite 
concentrations were higher among women compared to men for BDCIPP and DPHP, 
similar for ip-PPP, while tb-PPP concentrations were higher in men.  Metabolite 
concentration correlations among couples (n=229) were weak for all metabolites 
(0.20<r<0.31, p≤0.01), with the exception of tb-PPP (r=0.70, p=0.04), that was detected 
at low rates (<15% above MDL) for both women and men (Table IV.3).  Concentrations 
of DPHP for men were also weakly correlated to ip-PPP concentrations in women 
(r=0.14, p=0.04).  
 Adjusted percent change in OPE metabolite concentrations with self-reported 
PCP use for women can be found in Figure IV.1.  Use of nail polish was associated with 
a 134% increase (95% CI: 62, 235; p<0.0001) in DPHP concentrations as well as nail 
polish remover (77%; 95% CI: 21, 159; p=0.0004).  Increased concentrations of DPHP 
were associated with reported use of face moisturizer (60%; 95% CI: 15, 123; p=0.01).  
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Deodorant use was also associated with a 28% increase in DPHP (95% CI: 5, 57; 
p=0.02) and a 26% increase in ip-PPP (95% CI: 1, 55; p=0.04) concentrations.    We 
identified significant relationships with the use of colored cosmetics with DPHP and ip-
PPP concentrations (27%, 95% CI: 7, 49; p=0.01 and 26%, 95% CI:1, 55; p=0.01 
respectively).  Reported use of hair products including mousse, hair bleach, relaxer, and 
perm straightener was associated with a 27% increase (95% CI: 2, 58; p=0.04) in ip-
PPP concentrations while toothpaste was associated with a non-significant increase of 
80% (95% CI: -35, 395; p=0.25).  Yet for men, only mouthwash was significantly 
associated with a 31% increase in DPHP (95% CI: 3, 63; p=0.03) and total OPE (95% 
CI: 8, 62; p=0.01) concentrations (Figure IV.2).   
 Vinyl glove use was associated with a 32% increase in BDCIPP and ip-PPP 
concentrations among women (95% CI: -20, 120; p=0.27 and 95% CI: -11, 97; p=0.17), 
while concentrations of DPHP were related to a 27% decrease (95% CI: -45, -3; p=0.03) 
with reported hand dishwashing liquid use (Figure IV.3).  Vinyl glove use in men had the 
highest associated increase in BDCIPP (95% CI: -12, 314; p=0.10), DPHP (95% CI: 9, 
232; p=0.02), and total OPE (95% CI: 3, 175; p=0.04) concentrations (92%, 92%, and 
68%, respectively) (Figure IV.4).  While not statistically significant, concentrations of 
BDCIPP were associated with an 85% increase with the use of paints/solvents (95% CI: 
-73, 169; p=0.77) while fabric softener use was related to an 57% increase in BDCIPP 
(95% CI: -74, 25; p=0.16) and 63% increase in DPHP (95% CI: -65, 12; p=11) 
concentrations. 
 In our sensitivity analysis, nail polish use was associated with a 306% increase in 
urinary DPHP concentrations (95% CI: 129, 610; p<0.0001) among women with 
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samples collected between 2010-2015.  Metabolite concentrations of ip-PPP in women 
increased by 40% in association with deodorant use during 2010-2015 (95% CI: 5, 88; 
p=0.02).  All significant associations with OPEs and PCP and HP highlighted in our 
primary analysis remained the same or similar when only using observations collected 
during 2010 or later.  However, these associations disappeared when only using 
observations between 2005-2009 (data not shown).  No other significant associations 
were identified during this secondary analysis.        
Discussion 
We identified several associations between PCP use and DPHP concentrations, 
specifically with the use of nail polish, nail polish remover, face moisturizer, deodorant, 
and cosmetics in women.  Concentrations of ip-PPP were also associated with 
increased reported use of deodorant, cosmetics, and hair products.  We did not observe 
similar relationships with PCP use in men, only finding associations with DPHP and total 
OPE with mouthwash.  Overall, there were few significant associations identified with 
HP use.  Reported use of vinyl gloves was associated with elevated concentrations of 
all metabolites for both men and women.  Although most product use was associated 
with an increase in OPE metabolite concentration, dishwashing liquid use was 
significantly associated with a decrease in DPHP concentrations among women.   
 We found OPE concentrations to be slightly higher in women compared to men 
for BDCIPP and DPHP in this study.  The National Health and Nutrition Examination 
Survey (NHANES) reported similar results with slightly higher concentrations of DPHP 
in women (GM=0.92 μg/L) compared to men (GM=0.78 μg/L), yet concentrations of 
BDCIPP were slightly higher for men (GM=0.91 μg/L) compared to women (GM=0.80 
113 
 
μg/L) 3.  Concentrations of DPHP for men and women from NHANES were similar to our 
sample (women GM=0.91, men GM=0.75 μg/L), though BDCIPP metabolite 
concentrations were slightly higher for women (GM=0.91 μg/L) and lower for men 
(GM=0.62 μg/L).  A small study (n=53) in North Carolina found a slightly larger sex 
disproportion of DPHP with women having approximately a 2-fold higher urinary 
concentration (10β =1.84) compared to men (10β =0.98), although BDCIPP 
concentrations were comparable 12.  Similar to our findings, phthalate metabolites have 
also been found at higher concentrations in women compared to men, and phthalates 
are also used as plasticizers in various PCPs and HPs 38,39. 
 Along with the differences in OPE concentrations by sex, the lack of similar 
relationships between self-reported PCP use and OPE metabolite concentrations could 
possibly be a result of the episodic use patterns of PCPs, lifestyle, as well as different 
formulations of products targeted to each sex 3,33.  A US survey of 2,300 adults found 
the average women uses 12 products consisting of approximately 168 unique 
ingredients per day while men use an average of 6, exposing them to 85 unique 
chemicals in a single day 40.  Higher usage of both PCP and HP among women has 
also been reported in studies from the Netherlands, Switzerland, and South Korea 41–43. 
 Organophosphates have been largely associated with their use as FRs in 
polyurethane foam in furniture and cars, electronics, as well as components of the 
widely used FR mixture Firemaster ® 550 28,44–46.  However, non-halogenated 
compounds like TPHP and ITP are also used as plasticizers 8.  Plasticizers are 
frequently used to increase the flexibility of plastics and in the production of vinyl in PCP 
and HP 47,48.  This coincides with the majority of our relationships identified with 
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increasing concentrations of TPHP and ITP metabolites (DPHP and ip-PPP, 
respectively) with reported use of PCP and HP. TPHP is commonly listed as an 
ingredient in nail polishes where it is likely used to increase the flexibility of the polish 
after its application.  A small study from the California Environmental Protection Agency 
(Cal EPA) detected TPHP in five of 14 nail products tested 29.  Interestingly, when TPHP 
was detected, a common plasticizer, dibutyl phthalate (DBP) was not found.  Thus, 
TPHP is possibly replacing DBP in nail products as a plasticizer.  This potentially 
explains our strongest association of percent increase for DPHP concentrations (134%) 
with reported nail polish use which more than doubled (306%) when only using 
observations collected during 2010 or later.  Our findings also overlap with a prior study 
of urinary DPHP concentrations and nail polish application that found a larger increase 
in urine concentrations (7-fold) compared to our results, which could be a result of more 
rigorous and timely urine collection in their study design 30.  We also detected a 
significant association with nail polish remover and elevated DPHP concentrations 
(77%).  This result was unexpected as acetone, ethylene glycol, and gamma 
butyrolactone are the most common ingredients for nail polish remover 49.  While this 
could be a result of OPEs in the product, it is also possible that as nail polish is being 
removed, exposure via inhalation or dermal absorption is increased.  Or,  nail polish 
remover could be acting as a surrogate for nail polish as use of both products was 
correlated (p=0.001).  Deodorant use among women was also correlated with nail polish 
use (p=0.02) and surrogacy possibly explains this unexpected result.  In our secondary 
analysis we also observed a 40% increase in ip-PPP urine concentrations using 
observations between 2010-2015 (compared to a 20% increase using all observations) 
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for women who reported using deodorant.  Nail polish and deodorant were the only 
products to have a substantial difference in OPE concentrations when exploring the 
year of collection.  Along with TPHP replacing DBP as a plasticizer in nail polish, it is 
also possible that phthalates used in deodorants are also being replaced with OPES like 
TPHP or ITP 50.  These results further highlight the possibility of OPEs replacing 
phthalates as plasticizers around 2010 31.   
 We also observed a significant decrease in DPHP concentrations with reported 
dishwashing liquid use.  This is possibly due to reduced dermal absorption as a result of 
frequent hand washing which has been reported for several OPEs 51.  Although not 
significant, we also observed decreased OPE concentrations with reported conditioner 
and bar soap use in women and shampoo, toothpaste, and shaving cream use among 
men, which could also be a result of washing, rinsing, or bathing to decrease dermal 
absorption.     
 Weak correlations of metabolites among couples suggest that dust ingestion 
from OPEs in furniture foams from the home is not the sole exposure route/pathway. 
Organophosphate esters are characterized as semi volatile organic compounds and 
continuously divided between the gaseous and solid phases. Thus, exposure to OPEs 
is possibly from multiple routes/pathways in which they are ingested as well as 
absorbed through the skin from PCP and HP use 52.  These weak correlations could be 
a result of differences in PCP and HP use patterns between sexes, or varying 
metabolism rates of OPEs among women and men.  
 Although novel, our study was subject to several limitations.  The PCP and HP 
questionnaire did not capture frequency, amount, or the last time of product use in 
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relation to urine sample collection.  However, due to the exploratory nature of this study, 
additional adjustment for these factors may have saturated our model and biased our 
results towards the null.  OPE exposure differences among couples could be a result of 
being in different environments throughout the day as OPEs have also been highly 
detected in cars and offices 7.  Despite being a comprehensive PCP and HP use 
questionnaire, our results may be susceptible multiple statistical comparisons.  
Nevertheless, our results coincide with the prior studies of DPHP and nail polish 30.   
 Several factors may have attenuated the effect estimates in our analysis.  Due to 
the rapid metabolism of OPEs, resulting in half-lives of several hours, as well as the 
episodic nature of PCP and HP use, our effect sizes of our relationships may be 
underestimated 17,33.  However, studies from the same cohort found moderate temporal 
variability among OPE concentrations over a three month time period 17,23.  While our 
study consisted of approximately 230 couples, we had almost twice as many women’s 
urine samples (n=638) compared to men’s (n=335).  A difference in repeated 
measurements could explain the sex differences we observed in our relationships with 
PCP and HP.  OPE concentrations in women have also been found to be higher 
compared to men, consistent with ?our present findings 3.  Our study population was 
comprised primarily of White, non-smoking, highly educated couples who were 
subfertile, which could also have resulted in modest results as prior studies have found 
higher OPE concentrations associated with lower socioeconomic status (SES) and non-
White populations 3,19.  Thus, our results may only be generalizable to similar 




 Our study also had several strengths.  To the best of our knowledge, we are the 
most comprehensive study to date to assess the potential relationships of OPE 
metabolite concentrations with self-reported PCP and HP use.  Our study design also 
allowed for increased precision in measurement of OPE metabolites due to multiple 
urine samples as well as multiple questionnaire responses per participant.  The 
prospective study design also decreased the possibility of systematic error as the 
questionnaire referenced product use only 24 hrs. prior to urine sample collection.  Also, 
as our sample consisted of couples, we were able to identify the lack of correlation 
between metabolites among couples likely residing in the same residence to exploit the 
possibility for alternate exposure routes and pathways besides dust from the home.  
Finally, the longevity of this well-established cohort spanning 10 years of sample 
collection allowed for the exploration of temporal associations correlating to formulation 
changes of PCP and HPs.  
Conclusion 
To the best of our knowledge, this is the first study to characterize the 
relationships of OPE metabolites and self-reported PCP and HP use.  While metabolites 
BDCIPP, DPHP, and ip-PPP were highly detected among women and men, 
concentrations in women were slightly higher.  Correlations of metabolites were weak 
among couples which is consistent with our different results among sexes.  Similar to 
the only prior study of DPHP in urine and nail polish, we identified an association of 
increased DPHP concentrations in urine (134%) with reported nail polish use.  This 
association nearly doubled (306% increase) when only using observations from 2010-
2015.  We also identified significant associations with reported use of other PCPs 
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including: nail polish remover, face moisturizer, colored cosmetics, and deodorant for 
women.  Relationships with HP use were fewer, yet vinyl glove use in men was 
associated with a 92% increase in DPHP concentrations.  These results suggest OPEs 
are not only used as FRs, but possibly as plasticizers in these products and also 
contribute to internal exposure.  Furthermore, it is possible this replacement occurred 
during 2010 as highlighted by our differences in associations using observations 
between 2005-2009 compared to those between 2010-2015.  Our results identify the 
necessity of more targeted studies to further investigate the prevalence of OPE 
compounds, especially non-halogenated aryl phosphates TPHP and ITP, in PCPs and 
HPs highlighted by our results. 
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Table IV.1: Summary of reported personal care product use within 24 hours of OPE 
urine sample collection among Environment and Reproductive Health (EARTH) study 
participants between 2005-2015 (n=230 women; n=229 men). 
 
Personal Care Product Yes (n, %) No (n, %) Missing (n, %) 
Women (n=638 samples)    
   Deodorant (378, 59.2) (101, 15.8) (159, 24.9) 
   Shampoo (367, 57.5) (112, 17.6) (159, 24.9) 
   Toothpaste (364, 57.1) (3, 0.4) (271, 42.5) 
   Conditioner / Cream 
Rinse 
(323, 50.6) (156, 24.5) (159, 24.9) 
   Bar Soap (321, 50.31) (157, 24.6) (160, 25.1) 
   Hand/Body Lotion (298, 46.8) (181, 28.4) (159, 24.9) 
   Colored Cosmetics (203, 31.8) (276, 43.3) (159, 24.9) 
   Face Moisturizer/ Lotion (146, 22.9) (37, 5.8) (455, 71.3) 
   Hair Spray/ Hair Gel (134, 21.0) (341, 53.4) (163, 25.5) 
   Liquid Soap/ Body Wash (128, 20.1) (55, 8.6) (455, 71.3) 
   Mouthwash (115, 18.0) (349, 54.7)  (174, 27.3) 
   Cologne or Perfume (114, 17.9) (365, 57.2) (159, 24.9) 
   Other Toiletries (94, 14.7) (54, 8.4) (490, 76.8) 
   Other hair products (92, 14.4) (386, 60.5) (160, 25.1) 
   Hand Sanitizer (80, 12.5) (286, 44.8) (272, 42.6) 
   Shaving Cream (76, 11.9) (403, 63.2) (159, 24.9) 
   Suntan / Sunblock Lotion (49, 7.7) (430, 67.4) (159, 24.9) 
   Nail Polish Remover (23, 3.6) (159, 24.9) (456, 71.5) 
   Nail Polish (21, 3.3) (457, 71.6) (160, 25.1) 
Men (n=335 samples)    
   Deodorant (211, 63.0) (37, 11.0) (87, 26.0) 
   Shampoo (204, 60.9) (44, 13.1) (87, 26.0) 
   Toothpaste (190, 56.7) (4, 1.2) (141, 42.1) 
   Bar Soap (177, 52.8) (71, 21.2) (87, 26.0) 
   Shaving Cream (87, 13.6) (161, 43.8) (87, 26.0) 
   Mouthwash (79, 23.6) (169, 50.4) (87, 26.0) 
   Hair Spray/ Hair Gel (74, 22.1) (174,51.9) (87, 26.0) 
   Hand/Body Lotion (63, 18.8) (184, 54.9) (88, 26.3) 
   Liquid Soap/ Body Wash (59, 17.6) (48, 14.3) (228, 68.1) 
   Hand Sanitizer (54, 16.1) (139, 41.5) (142, 42.4) 
   Cologne or Perfume (41, 12.2) (206, 61.5) (88, 26.3) 
   Conditioner / Cream 
Rinse 
(40, 11.9) (208, 62.1) (87, 26.0) 
   Face Moisturizer/ Lotion (18, 5.4) (90, 26.9) (227, 67.8) 
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   Aftershave (16, 4.8) (232, 69.3 (87, 26.0) 
   Other hair products (16, 4.8) (230, 68.7) (89, 26.6)  
   Other Toiletries (14, 4.18) (77, 23.0) (244, 72.8) 
   Suntan / Sunblock Lotion (7, 2.1) (241, 71.9) (87, 26.0) 
Other hair products include: mousse, hair bleach, relaxer, perm straightener; Other  
toiletries include: wax, Vaseline, lip balm; Reported use of Personal care products n <5 were not listed 
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Table IV.2: Summary of reported household product use within 24 hours of OPE urine 
sample among EARTH participants between 2005-2015 (n=230 women; n=229 men). 
Household Product Yes (n, %) No (n, %) Missing (n, 
%) 
Women (n=638)    
   Laundry Detergent (147, 23.1) (332, 52.3) (159, 24.9) 
   Hand Dishwashing 
Liquid 
(123, 19.3) (60, 9.4) (455, 71.3) 
   Cleaners (99, 15.5) (380, 59.6) (159, 24.9) 
   Fabric Softener (63, 9.9) (416, 65.2) (159, 24.9) 
   Vinyl Gloves (28, 4.4) (451, 70.7) (159, 24.9) 
   Furniture Polish (9, 1.4) (470, 73.7) (159, 24.9) 
   Vinyl Boots (8, 1.3) (471, 73.8) (159, 24.9) 
Men (n=335)    
   Hand Dishwashing 
Liquid 
(59, 17.6) (49, 14.6) (227, 67.8) 
   Cleaners (38, 11.3) (210, 62.7) (87, 26.0) 
   Laundry Detergent (22, 6.6) (226, 67.5) (87, 26.0) 
   Vinyl Gloves (9, 2.7) (238, 71.0) (88, 26.3) 
   Fabric Softener (8, 2.4) (240, 7.2) (87, 26.0) 
   Paint/ Solvents (5, 1.5) (103, 30.7) (227, 67.8) 




Table IV.3: Spearman correlation coefficients of urinary OPE metabolites among 
couples in the EARTH cohort (n=229 couples). 

















 BDCIPP DPHP ip-PPP tb-DPHP 







0.03 0.58 0.06 0.41 -0.26 0.11 
DPHP 0.06 0.33 0.22 0.0002 0.14 0.04 -0.05 0.76 
ip-PPP 0.06 0.42 0.06 0.43 0.20 0.01 -0.05 0.81 






Figure IV.1: Adjusted percent change in urinary OPE metabolite concentrations with 
self-reported PCP use for 230 women from the EARTH cohort.  
  OPE Metabolite 
PCP n BDCIPP DPHP ip-PPP ∑OPE 
Deodorant 378 -6 28* 26* 20 
Shampoo 367 11 2 2 13 
Toothpaste 364 12 48 80 49 
Conditioner 323 -11 3 21* 5 
Bar Soap 321 -20 -1 1 -16 
Hand/Body Lotion 298 -2 6 4 -5 
Colored Cosmetics 203 -15 27* 26* 14 
Face Moisturizer 146 13 60* -3 23 
Hair Spray/Gel 134 -7 14 21 0 
Liquid Soap 128 16 4 2 16 
Mouthwash 115 -3 -6 8 9 
Cologne/Perfume 114 -8 17 19 13 
Other Toiletries 94 -16 2 -13 -21 
Other Hair Products 92 13 19 27* 14 
Hand Sanitizer 80 -25 5 6 0 
Shaving Cream 76 13 6 -2 -21 
Suntan /Block Lotion 49 -2 6 4 16 
Nail Polish Remover 23 32 77** 21 32 
Nail Polish 21 -34 134** 5 52 
Heat map for adjusted percent change in PFR metabolite concentrations with self- reported PCP within 
24 hr. of urine sample collection (n=638 urine samples).  Models are adjusted for Specific Gravity (SG), 
age, BMI, race (other/white), smoking status (never/ever), education & season; * p<0.05, ** p<0.005 
                                                                                                                 Percent Change 













Figure IV.2: Adjusted percent change in urinary OPE metabolite concentrations with 
self-reported PCP use for 229 men from the EARTH cohort. 
 
Heat map for adjusted percent change in OPE metabolite concentrations with self- reported PCP within 
24 hr. of urine sample collection (n=335 urine samples).  Models are adjusted for Specific Gravity (SG), 
age, BMI, race (other/white), smoking status (never/ever), education & season; * p<0.05 
 
                                                                                                                 Percent Change 











  PFR Metabolite 
PCP  n BDCIPP DPHP ip-PPP ∑OPE 
Deodorant 211 -10 -19 2 -14 
Shampoo 204 -9 -9 23 -6 
Toothpaste 190 -10 -16 28 -8 
Bar Soap  177 4 -12 12 -4 
Shaving Cream 87 -10 -14 1 -10 
Mouthwash 79 26 31* 16 31* 
Hair Spray/Gel  74 6 16 16 20 
Hand/Body Lotion 63 4 -16 -10 -7 
Liquid Soap 59 26 -11 -23 -1 
Hand Sanitizer 54 -11 -16 -20 -13 
Cologne/Perfume 41 34 -4 12 6 
Conditioner 40 -4 -8 8 -8 
Face Moisturizer 18 -3 -6 1 11 
Aftershave 16 7 9 -44 8 
Other Hair Products  16 6 14 -11 3 
Other Toiletries 14 -6 -7 8 -10 
Suntan/Block Lotion     7 30 -32 -35 -1 
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Figure IV.3. Adjusted percent change in urinary OPE metabolite concentrations with 
self-reported household product use for 230 women from the EARTH cohort. 
  PFR Metabolite 
Household Product n BDCIPP DPHP ip-PPP ∑OPE 
Laundry Detergent 147 -4 -10 1 -10 
Hand Dishwashing 
Liquid     
123 0.20 -27* 1 -8 
Cleaners 99 -3 -6 6 3 
Fabric Softener 63 -20 -6 -12 -21 
Vinyl Gloves 28 32 13 32 40 
Furniture Polish 9 12 -10 -18 -13 
Vinyl Boots 8 16 -14 -27 5 
Heat map for adjusted percent change in PFR metabolite concentrations with self- reported household 
product within 24 hr. of urine sample collection (n=638 urine samples).  Models are adjusted for Specific 
Gravity (SG), age, BMI, race (other/white), smoking status (never/ever), education & season; * p<0.05 
                                                                                       

















Figure IV.4. Adjusted percent change in urinary OPE metabolite concentrations with 
self-reported household product use for 229 men from the EARTH cohort. 
  PFR Metabolite 
Household Product n BDCIPP DPHP ip-PPP ∑OPE 
Hand Dishwashing 
Liquid 
59 26 0 8 6 
Cleaners 38 7 14 12 15 
Laundry Detergent 22 31 -24 -2 -2 
Vinyl Gloves 9 92 92* 28 68* 
Fabric Softener 8 57 63 -14 -34 
Paint/Solvent 5 85 -23 -39 -36 
Heat map for adjusted percent change in PFR metabolite concentrations with self- reported household 
product within 24 hr. of urine sample collection (n=335 urine samples).  Models are adjusted for Specific 
Gravity (SG), age, BMI, race (other/white), smoking status (never/ever), education & season; * p<0.05 
                                                                                                                  



















Chapter V Appendix 
 
Table IV.A.1. Regression coefficients (95% CI) for reported use of personal care products (PCP) and OPE 
metabolites within 24 hours of urine specimen collection for 230 women from the EARTH cohort. 
 
  OPE Metabolites a 
  BDCIPP DPHP ip-PPP ∑OPE 
 n b B 95%CI p B 95%CI p B 95%CI p B 95%CI p 
























































































































































































































































































a Natural log transformation; b Reported ‘yes’ to PCP use within 24 hr. of PFR sample; Models adjusted for Specific gravity (SG), age, BMI, 




76 0.12 (-0.19, 
0.44) 
0.44 0.06 (-0.18, 
0.30) 





































































Table IV.A.2. Regression coefficients (95% CI) for reported use of personal care products (PCP) and OPE            
metabolites within 24 hours of urine specimen collection for 229 men from the EARTH cohort. 
  OPE Metabolites a 
  BDCIPP DPHP ip-PPP ∑OPE 







































































































































































































































14 -0.06 (-0.86, 
0.75) 
0.89 -0.07 (-0.57, 
0.43) 
0.78 0.08 (-0.53, 
0.69) 








7 0.26 (-0.60, 
1.12) 
0.56 -0.38 (-1.00, 
0.24) 
0.22 -0.43 (-1.10, 
0.24) 
0.20 -0.01 (-0.56, 
0.54) 0.98 
a Natural log transformation; b Reported ‘yes’ to PCP use within 24hrs. of urine sample; Models adjusted for Specific gravity (SG),                       




Table IV.A.3. Regression coefficients (95% CI) for reported use of household products (HP) and OPE metabolites        
within 24 hours of urine specimen collection for 230 women from the EARTH cohort. 
  OPE Metabolites a 
  BDCIPP DPHP ip-PPP ∑OPE 












































































































a natural log transformation; b Reported ‘yes’ to HP within 24hrs. of urine sample; c n=183; Models adjusted for Specific gravity (SG),                   




Table IV.A. 4. Regression coefficients (95% CI) for reported use of household products (HP) and OPE 









a natural log transformation; b n= reported using household products within 24hrs. of urine sample; c n=108; d n=247; Models        
adjusted for Specific gravity (SG), age, BMI, race (other/white), smoking status (never/ever), education & season; Reported use             








  OPE Metabolites a 
  BDCIPP DPHP ip-PPP ∑OPE 


































































































Table IV.A. 5. Adjusted percent change (95% CI) for reported use of personal care products (PCP) and PFR 
metabolites within 24 hours of urine specimen collection for 230 women. 
  PFR Metabolites  




 change 95%CI p 
% 
change 95%CI p 
%  
change 95%CI p 
%  
change 95%CI p 
Deodorant         378 -6 (-28, 
22) 
0.64 28 (5, 57) 0.02 26 (1, 55) 0.04 20 (-6, 54) 0.14 

































Bar Soap 321 -20 






0.94 -16 (-33, 4) 0.10 
Hand/Body 
Lotion 















(-32, 6) 0.14 27 (7, 49) 0.01 26 (5, 49) 0.01 14 (-7, 39) 0.21 
Face 
Moisturizer 














134 -7 (-27, 
19) 

































114 -8 (-29, 
19) 




















92 13 (-15, 
49) 



















76 13 (-17, 
55) 
0.44 6 (-16, 
35) 
0.61 -2 (-24, 
26) 




 a Reported ‘yes’ to PCP use within 24 hr. of PFR sample; Models adjusted for Specific gravity (SG), age, BMI, race (other/white), smoking 


































Nail Polish  21 -34 












Table IV.A.6. Adjusted percent change (95% CI) for reported use of personal care products (PCP) and PFR metabolites 
within 24 hours of urine specimen collection for 229 men.  
  PFR Metabolites  




change 95%CI p 
%  
change 95%CI p 
%  
change 95%CI p 
%  





0.65 -19 (-41, 9) 0.16 2 
(-26, 
42) 
































0.40 -4 (-22, 19) 0.70 
Shaving 
Cream 
87 -10 (-34, 
25) 
0.53 -14 (-31, 8) 0.21 1 
(-21, 
30) 
0.94 -10 (-26, 11) 0.33 
Mouthwash 79 26 (-9, 73) 0.16 31 (3, 63) 0.03 16 (-10, 
48) 
0.24 31 (8, 62) 0.01 
Hair 
Spray/Gel 
74 6 (-24, 
48) 
0.74 16 (-9, 48) 0.22 16 
(-10, 
51) 
0.24 20 (-3, 46) 0.09 
Hand/Body 
Lotion 
63 4 (-27, 
48) 
0.82 -16 (-34, 8) 0.19 -10 
(-31, 
19) 
0.47 -7 (-25, 16) 0.52 





0.49 -23 (-44, 7) 0.12 -1 (-25, 32) 0.97 
Hand 
Sanitizer 





0.58 -20 (-41, 7) 0.14 -13 (-32, 12) 0.26 
Cologne/ 
Perfume 








0.50 6 (-18, 38) 0.63 








0.62 -8 (-29, 20) 0.55 
Face 
Moisturizer 








0.99 11 (-26, 67) 0.60 





0.69 -44 (-58, 4) 0.07 8 (-25, 58) 0.66 
Other Hair 
Products 








0.60 3 (-30, 51) 0.87 
Other 
Toiletries 
14 -6 (-58, 
112) 
0.89 -7 (-43, 
54) 
0.78 8 (-41, 
99) 





7 30 (-45, 
206) 
0.56 -32 (-63, 
27) 
0.22 -35 (-67, 
27) 
0.20 -1 (-43, 72) 0.98 
a Reported ‘yes’ to PCP use within 24hrs. of urine sample; Models adjusted for Specific gravity (SG), age, BMI, race (other/white), smoking status                                         




Table IV.A.7. Adjusted percent change (95% CI) for reported use of household products (HP) and PFR metabolites  
within 24 hours of urine specimen collection for 230 women (n=479). 
  PFR Metabolites a 





change 95%CI p 
%  
change 95%CI p 
% 
 
change 95%CI p 
% 
 change 95%CI p 
Laundry 
Detergent 





















































(-41, 5) 0.11 






































a Reported ‘yes’ to HP within 24hrs. of urine sample; b n=183; Models adjusted for Specific gravity (SG), age, BMI, race (other/white), smoking 





Table IV.A.8.  Adjusted percent change (95% CI) for reported use of household products (HP) and PFR metabolites 
within 24 hours of urine specimen collection for 229 men (n=248). 
  PFR Metabolites a 




change 95%CI p 
% 
change 95%CI p 
% 
change 95%CI p 
% 































22 31 (-21, 
116) 
0.30 -24 









9 92 (-12, 
314) 
0.10 92 


















(-61, 9) 0.10 
Paint/Solven
t b 











a n= reported using household products within 24hrs. of urine sample; b n=108; c n=247; Models adjusted for Specific gravity (SG), age,             





AIM 3 Part B:  The Association Between Urinary Concentrations of 
Organophosphate Ester Metabolites and Semen Parameters Among Men from a 
Fertility Clinic   
 
Abstract 
Background: The use of organophosphate esters as flame retardants has steadily 
increased as brominated compounds have been or are being phased out.  OPEs have 
half-lives from hours to days, yet human exposure is widespread.  Animal studies have 
shown adverse impacts on male reproduction, but human data are lacking.  The 
objective of this study was to investigate the associations between urinary 
concentrations of OPE metabolites and semen parameters. 
Methods: A subset of 220 men from an existing longitudinal cohort of couples was 
recruited from Massachusetts General Hospital fertility clinic between 2005 and 2015.  
Men having a female partner currently in the study and providing at least one urine 
sample for OPE measurement during an in vitro fertilization (IVF) cycle were eligible.  
Semen parameters included sperm count, concentration, motility, and morphology; 
some men had samples measured from multiple clinic visits (up to five visits; n=269 
semen samples).  Metabolites [bis(1,3-dichloro-2-propyl) phosphate (BDCIPP), diphenyl 
phosphate (DPHP), isopropylphenyl phenyl phosphate (ip-PPP), tert-butylphenyl phenyl 
phosphate (tb-PPP) and bis(1-chloro-2-propyl) phosphate (BCIPP)] were measured in  
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urine samples (between one and five urine samples per participant; n=355 urine 
samples; n=83 participants >1 urine sample).  Semen parameters were evaluated  
continuously and dichotomized for models. Metabolites were assessed for associations 
with semen parameters as continuous and categorized into quartiles using multivariable 
generalized mixed models, adjusted for specific gravity, age, BMI, smoking, and 
abstinence period. 
Results: Metabolites BDCIPP, DPHP, and ip-PPP were detected in a high proportion of 
urine samples (85%, 86%, and 65% respectively). Concentrations varied by season of 
collection, particularly for BDCIPP where samples collected in the summer were 
approximately 2-fold higher than concentrations of other seasons (p-value<0.0001).  
The odds of having a sperm count less than 39 mil/ejaculate decreased by 20% for 
increasing BDCIPP concentrations (p-value=0.04).  When regressing semen 
parameters on OPE metabolite quartiles, some negative associations were observed for 
individual quartiles among sample volume and morphology, but overall associations 
were weak and inconsistent. 
Conclusion:  Detection rates were high for BDCIPP, DPHP, and ip-PPP.  We did not 
observe consistent associations between OPE metabolites and semen parameters.  
Due to the high prevalence of exposure, further investigation of other potential health 





 Infertility, the inability to conceive after one year of unprotected intercourse, 
affects approximately one out of every six couples 1.  In 2002, a national survey 
estimated two million couples in the US suffer from infertility 2.  An increase in infertility 
is partially related to the postponement of first birth 3,4.  However,  aside from advanced 
age, genetic risk factors, psychosocial factors, and environmental agents can also 
impair fertility 5,6. 
 The underlying cause of infertility may be related to female or male factors or a 
combination of both.  In 2002, approximately 20% of male participants in the National 
Survey of Family Growth (NSFG) reported fertility problems in the US 7.  However, this 
estimate is likely modest as only men from couples struggling to conceive will seek 
fertility evaluation, thus male factor infertility is thought to be underdiagnosed  7,8.  In 
2002, the cost of male factor infertility alone was $17 million US dollars, which does not 
include the additional $18 billion for assisted reproductive technology treatment 1.   
 To date, a semen analysis measuring sperm count, concentration, motility, 
morphology, and volume remains the primary evaluation for male factor infertility 8,9.  A 
recent global meta-analysis found an approximate 50% reduction in total sperm count 
and sperm concentration among men from Western countries over the last several 
decades, regardless of fertility diagnosis 10.    Semen quality is also associated with 
other various health outcomes.  A study of Finnish men found an increase risk in 
testicular cancer among those with poor semen quality 11, while a Danish study found  
subpar semen associated with a shorter life span 12.  Many environmental agents such 
as glycol ethers, pesticides, and phthalates are also known to impact semen quality 6.   
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 Among possible environmental chemicals of concern for reproductive health are 
organophosphate esters (OPEs), which are increasingly being used as flame retardants 
(FRs).  The use of OPEs has grown due to their use as replacement chemicals for the 
phased-out of polybrominated diphenyl ethers (PBDEs).  As their prevalence rose, 
OPEs became and remain a high production volume chemical.  Today they are 
commonly applied to materials for use as either a flame retardant, or as a plasticizer, 
therefore are common in polyvinyl chloride (PVC), hydraulic fluids, and polyurethane 
foam (PUF) in cars and furniture 13–15.  OPE s include both chlorinated alkyl esters such 
as tris(2-chloroisopropyl) phosphate (TCIPP) and tris(1,3-dichloroisopropyl) phosphate 
(TDCIPP), and non-halogenated aryl phosphates such as triphenyl phosphate (TPHP) 
13,16.  Often considered ‘additive’ compounds, the weak bonds allow volatilization into air 
and settlement in dust.  OPE s have been detected in the dust of homes, cars, and 
offices 16,17.  Unlike brominated flame retardants, OPEs are considered non-persistent, 
with a short half-life in humans ranging from several hours to days, yet they are 
detected in nearly 100% of urine samples from men 18, pregnant women 19 , and 
children 20.   
 
 To date, studies assessing the health effects of OPEs are limited, yet animal and 
in vitro studies suggest these compounds act as endocrine disrupting chemicals.  A 
study of TPHP and tris(2-chloroethyl) phosphate (TCEP) in mice found a disruption of 
gene expression for testosterone synthesis and oxidative stress 21, while an in vitro 
study of mouse Leydig cells found a disruption in steroid production 22.  A small study of 
US men detected inverse relationships of bis(1,3-dichloropropyl) phosphate (BDCPP) 
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and diphenyl phosphate (DPHP) concentrations in urine with sperm concentration and 
motility 23.  To the best of our knowledge, this prior analysis is the only human study to 
date to assess the relationship of OPE s with semen parameters.  In our present work, 
we expand upon this preliminary evidence with a larger cohort to characterize the 
relationship between five OPE  metabolites: bis(1-chloro-2-propyl) phosphate (BCIPP), 
bis(1,3-dichloro-2-propyl) phosphate (BDCIPP), diphenyl phosphate (DPHP), 
isopropylphenyl phenyl phosphate (ip-PPP), tert-butylphenyl phenyl phosphate (tb-PPP) 
with semen parameters in men attending a fertility center.  
Methods 
Participant Recruitment 
 Participants from this analysis are a subset of men from the Environment and 
Reproductive Health (EARTH) study, a larger cohort assessing the impact of 
environmental agents on reproductive health.  Participation and recruitment have been 
described elsewhere 24.  Briefly, men (18-54 years of age) attending the Massachusetts 
General Hospital fertility clinic between 2005 and 2015 were eligible.  Participants 
originated from couples whose infertility diagnosis was either male factor, female factor, 
or a combination of both.  Along with having a female partner enrolled in the EARTH 
study, men must also have provided at least one urine sample for OPE measurement 
during an in vitro fertilization (IVF) cycle.  Thus, men who provided more than one 
sample were part of a couple who may have had more difficulty achieving pregnancy.  
Prior vasectomy or hormone supplementation were the only exclusion criteria.  Informed 
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consent was signed by each participant and Institutional Review Board approval was 
received by all institutions.         
Semen Collection and Analysis 
 Semen collection and analysis have been previously described 24,25.  Briefly, men 
abstained from ejaculation for 48 hours prior to sample collection into plastic specimen 
cup.  Men provided up to five samples depending on the number of fertility treatments, 
additional fertility evaluation, or a combination of both.  An andrologist quantified sample 
volume (mL) with a graduated pipet.  Sperm concentration (mil/mL) and motility (% 
motile) was determined using a computer-aided semen analyzer (CASA, version 10 
HTM-IVOS; Hamilton Thorne Research, Beverly, MA).  Samples (5 µL) were collected 
on a disposable Leja Slide (Spectrum Technologies, CA, USA) and placed into a pre-
warmed (37°C) counting chamber (Sefi-Medical Instruments, Haifa, Israel) before 
assessing concentration and motility.  Among each sample, at least 200 sperm cells 
were analyzed from four different fields.  Progressive motility was graded in accordance 
to the WHO’s assessment criteria of active movement (linearly or in a large circle), 
regardless of velocity (WHO, 2010).  The product of sperm concentration and sample 
volume determined sperm count (mil/ejaculate) while progressive motility count 
(mil/ejaculate) was calculated by multiplying progressive motility and total sperm count.  
Fresh semen samples were allowed to dry on two prepared slides and prepared for 
morphology (% normal) assessment with a microscope using an oil-immersion 100x 
objective (Nikon, Tokyo, Japan).  A minimum of 200 cells per slide were analyzed for 
each specimen.  Classification of normal or subnormal morphology was determined 
using strict Kruger scoring criteria 26.  Quality assurance and control procedures in the 
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laboratory were conducted for sperm morphology smears weekly, as well as quarterly 
and biannual evaluations for technicians.  
Urine Collection and Analysis  
 Urine samples (from up to five cycles) were collected in sterile polypropylene 
cups on the day of semen sample collection.  Most men provided one urine sample 
(n=220), while 83 provided two samples and 26 provided three (n≤4 provided four or 
more samples).  Prior to being frozen (-80°) and stored, specific gravity (SG) was 
measured using a handheld refractometer (National Instrument Company, Inc., Austin, 
TX).  For metabolite analysis, samples were shipped overnight on dry ice to Dr. 
Stapleton’s lab at Duke University (Durham, NC).   
 Analytic methods for metabolites: BCIPP, BDCIPP, DPHP, ip-PPP, and tb-PPP 
have been previously described 27.  Briefly, 5 ml aliquots were thawed and transferred to 
test tubes and spiked with internal standards (d10-BDCIPP = 80 ng, d10-DPHP = 60 ng) 
before being acidified (pH <6.5) with formic acid and diluted with 1:1 with water.  Solid 
phase extraction (SPE) was used to concentrate and clean samples before drying via 
nitrogen stream and spiked with the recovery standard (13C2-DPHP = 81.5 ng).  Extracts 
were analyzed using negative electrospray ionization liquid chromatography tandem 
mass spectrometry (LC-MS/MS) detailed previously 27.  Optimal parameters under 
multiple reaction conditions were used to acquire data.  The internal standard used for 
BCIPP and BDCIPP was d10-BDCIPP, while quantification of DPHP, ip-DPHP, and tb-
DPHP was performed using d10-DPHP.   
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 Quality assurance and control procedures for LC-MS/MS have been described 
previously 28.  Briefly, samples were processed in multiple batches including five blanks 
per batch (5 ml Milli-Q water); each batch providing a distinct method detection limit 
(MDL).  MDLs were designated as three times the standard deviation of laboratory 
blanks and ranged from:  0.07-0.17 pg/ml for BCIPP, 0.02-0.11 pg/ml for BDCIPP, 0.09-
0.18 pg/ml for DPHP, 0.06-0.12 pg/ml for ip-PPP, and 0.04-0.15 pg/ml for tb-PPP.  
Urine samples from previous studies were pooled to establish a standard reference 
material (SRM) and routinely analyzed.  Duplicates of two-subsamples were analyzed to 
evaluate precision.      
Statistical Analysis 
 Descriptive statistics for OPE metabolites, semen parameters, and demographic 
factors were calculated.  Values below MDL for metabolites were imputed as MDL/√2.  
Metabolites were presented as uncorrected and adjusted for SG as: CSG = C*[(SGM-
1)/(SGi -1)], where CSG = SG-adjusted urinary metabolite concentration, C = urinary 
metabolite concentration, SGM = mean SG for the population, and SGi = SG for an 
individual sample 29.  We evaluated bivariate associations among OPE metabolites, 
semen parameters, and demographic factors using Spearman correlation coefficients, 
Wilcoxon rank-sum tests, and Kruskal-Wallis tests as appropriate.  An aggregate 
variable (∑OPE) was imputed by summing the urinary molar concentrations for 
metabolites BDCIPP, DPHP, and ip-PPP.  Intraclass correlation coefficients (ICC) and 
95% confidence intervals for metabolites (uncorrected and SG corrected) and semen 
parameters were calculated to assess variability between samples of each participant.  
All metabolites and semen parameters presenting as right-skewed were transformed by 
151 
 
natural logarithm for further statistical modeling.  OPE metabolites were evaluated as 
continuous variables and quartiles except for tb-PPP with low detection rate (11.34 %) 
was modeled as detect/non-detect.  Sperm parameters were evaluated both 
continuously and dichotomized using WHO reference level for sperm: count (< 
39mil/ejaculate), concentration (< 15 mil/mL), motility (< 40%), progressive motility 
(<32%), and morphology (< 4% normal) (WHO, 2010).  Initially, crude associations were 
calculated among OPE metabolites and semen parameters (Table V.A.1).  Bivariate 
tests for possible covariates: age (n=2 missing), BMI (n=3 missing), abstinence period 
(n=71 missing), race (n=2 missing), smoking status (n=2 missing), education (n=53 
missing), and season of collection (n=0 missing) along with biological plausibility and a 
priori knowledge were used to select covariates for modeling (Table V.A 2) 24,30,31.  
Potential confounding was defined as a 10% change in the effect estimate of OPE 
metabolites on semen parameters and investigated through covariates in Table V.A.2.  
Although season of sample collection was associated with OPE metabolites, it was not 
associated with semen parameters, fit criteria for confounding, or found to be an effect 
modifier, thus not included in final models.  Multivariable regression models, adjusted 
for SG, age, BMI, and abstinence period, were used to test associations using only the 
first urine and semen sample for all participants (data not shown).  Multivariable 
generalized mixed models with random intercepts using continuous, dichotomous, and 
quartiles for OPEs were used to assess associations with repeated exposures and/or 
semen parameters.  These models are optimal for IVF cohorts with multiple outcomes 
per person by accounting for within person correlations as well as account for an 
unbalanced study design (i.e. different number of cycles per person) when the 
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imbalance is not random (i.e. more cycles indicate increased difficulty achieving 
pregnancy).  Models included a fixed compound symmetry covariance structure.  
Continuous outcomes were analyzed using a normal distribution and identity link 
function while a binary distribution and logit link function was used for dichotomous 
outcomes.  To test for trends, the natural log transformed median urinary concentrations 
for each quartile was treated as a continuous variable in regression models.  We 
conducted a sensitivity analysis excluding SG measurements below 1.01 and above 
1.03 for multivariable models (Table V.A.3) to examine any effect of extreme urine 
concentrations.  Missing data were excluded from models.  All statistical analyses were 
carried out using SAS 9.4 (SAS Institute Inc., Cary, NC).     
Results 
Study Population 
 Demographic characteristics of our subsample from the EARTH study are 
displayed in Table V.1.  Demographics from this sample are similar to previous studies 
in similar cohorts 24 as well as national trends of men undergoing IVF 7 regarding age 
(mean=36.7 ± 5.1), BMI (27.2 ± 4.0), race or ethnicity (89% white), and education (80% 
college graduates).   
 The distribution of semen parameters among our sample is presented in Table 2.  
All parameters met WHO guidelines for normal sperm among more than half of 
participants (WHO, 2010).  Total sperm count and concentration exceeded the lower 
limit for normal sperm (43.4 and 15.9, respectively) in 90% of samples.  Conversely, 
less than half of participants had above average motility (45%) while 75% exceeded the 
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guideline for morphology (4%).  Participants provided semen (n=269) and urine (n=355) 
samples from up to five clinic visits, with the majority of men providing one to three.  
Repeated measures of semen parameters had moderately strong intraclass correlations 
(0.51-0.58), except motility (ICC=0.79) and progressive motility (ICC=0.71) which had 
stronger ICCs (Table V.A.4).       
 Distributions of OPE metabolites, as both uncorrected and SG-corrected are 
displayed in Table IV 3.  Metabolites BDCIPP, DPHP, and ip-PPP were detected in a 
high proportion of urine samples (85%, 86%, and 66% respectively).  We identified 
weak (r < 0.30) yet significant (p < 0.01) correlations among BDCIPP, DPHP, and ip-
PPP, and moderate (r=0.43) correlations between DPHP and tb-DPHP (p=0.01) (Data 
not shown).  Similarly, temporal stability between metabolite measurements (Table V.4) 
were weak-to-moderate (ICC <0.35) and decreased further when excluding non-detects 
and adjusting for SG, except for ∑OPE (r=0.67).  Concentrations varied by season of 
collection, particularly for BDCIPP where samples collected in the summer had the 
highest concentrations (p<0.0001) (Table IV.A.2).  
 When modeling OPE metabolites and semen parameters as continuous 
variables, there were no significant effect estimates from repeated measure models 
(Table V.5).  Whereas when semen parameters were dichotomized, elevated BDCIPP 
was associated with a decreased odds of low sperm count (OR=0.79, 95% CI=0.64, 
0.99; p=0.04).  Results were similar in a sensitivity analysis excluding extreme urine 
dilution concentrations (0.01 ≤ SG ≤ 1.03) (Table V.A.3).  When modeling OPE 
metabolites as quartiles, we identified a modest nonlinear trend (p=0.05) in progressive 
motility and ∑OPE (Table V.6).  The second quartile for DPHP (p=0.04) was positively 
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associated with sample volume, whereas the third quartile of ∑OPE (p=0.03) 
concentrations was inversely associated (Table V.6).  Semen concentration was 
positively associated with ∑OPE concentrations (Q3; p=0.04) (Table V.6).  DPHP 
concentrations between 0.66-1.21 μg/L (Quartile 3, p= 0.02) increased the odds of 
abnormal semen morphology (Table V.A.5).  However, overall p-trends were not 
statistically significant.   
Discussion 
 Although exposure was prevalent, overall, we did not observe consistent 
associations between OPE metabolites and semen parameters.  To our knowledge, this 
is the largest study to evaluate the relationship between OPE metabolites and semen 
quality.  Most semen parameters in our sample were above established reference levels 
(WHO, 2010) and within-participant reliability was moderate-to-strong for repeated 
samples.  Metabolites BDCIPP, DPHP, and ip-PPP were detected at high rates in urine 
and temporal reliability of repeated samples within participant was weak-to-moderate.  
While we found a decreased odds of a low sperm count (<39 mil/ejaculate) with 
increasing BDCIPP concentrations, overall associations were weak and inconsistent.  
Comparisons with other studies 
 To date, there are limited studies examining the potential for adverse health 
effects related to OPE exposure despite their high detection in various environmental 
media and respective metabolites in urine.  Parent compounds TDCPP and TPHP were 
detected in nearly all samples of house dust from a previous sample of  50 men from 
the EARTH cohort 32.  Similarly, a study in Durham, North Carolina (n=40 adults) 
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detected parent compounds to BDCIPP, BCIPP, and DPHP ( TDCIPP, TCIPP, and 
TPHP, respectively) in 100% of samples using silicone wrist bands and >95% of hand 
wipes 33.   
Studies characterizing OPEs in male populations are insufficient compared to 
those among women and children.  Yet, analogous to high detection rate in 
environmental media, metabolites BDICPP and DPHP were detected in >90% of 
individuals 18 and >95% of pooled samples 31.  Concentrations of BDCIPP in our 
samples were six-fold higher compared to a prior study (n=16) of adults in California 
(Median=0.09 ng/mL) 34.  Our samples of DPHP were also twice as high (Median= 0.44 
ng/mL), yet both were similar in having low detection of BCIPP.  A small sample (n=29) 
of office workers in Boston, MA also had slightly lower concentration of BDCIPP (SG-
adjusted Mean=408 pg/mil) 35.  However, distributions of BDCIPP, DPHP, and ip-PPP 
(GM= 0.64, 0.77, 0.32 µg/L respectively) were similar to a recent study of 211 females 
(n=563 samples) from the EARTH cohort (SG-adjusted GM= 0.66, 0.78, 0.22 µg/L 
respectively) 28 , yet considerably lower compared to more recent samples of pregnant 
women in Durham, North Carolina (uncorrected GM 1.8, 1.4, 6.8 µg/L respectively)  30 
and Shanghai, China (BDCIPP GM=1.2, DPHP GM=1.1 ng/mL) 36.   Exposure 
biomarker concentrations of these chemicals may follow a temporal trend, as our OPE  
concentrations are higher than prior studies, yet similar to samples collected during 
similar time periods; a recent study combining several cohorts from various parts of the 
US found a 15-fold increase in BDCIPP samples collected in 2015 compared to those 
collected in 2002 37.       
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The weak to moderate stability in repeated measurements in our sample was 
somewhat lower than reported from a previous study for BDICPP (ICC=0.55-0.72) and 
DPHP (ICC=0.35-0.51), although the sample period was considerably shorter (3 
months) compared to the present analysis (3 months-5 years) 18.  However, another 
study with a longer time period (12 months) found ICCs of DPHP to be somewhat lower 
and similar to our findings (ICC range 0.13-0.39) 38.   We identified a relationship with 
OPE concentrations and season of sample collection, where concentrations of BDCIPP 
(p<0.0001) were highest in summer (June-August), while DPHP (p=0.05) 
concentrations were highest in the winter (December-February).  A sample of adults 
spanning the US observed a similar seasonal relationship as BDCIPP concentrations in 
summer were 4.13 times higher than winter samples and contrary to our observations, 
DPHP concentrations were also highest in summer 37.  Similar results were found 
among a sample of pregnant women, where summer (June-August) concentrations of 
BDCIPP and DPHP were almost 4-fold and 60% higher, respectively compared to 
winter samples 30.  Thus, warmer climates may potentially impact OPE  exposure and 
explain the difference in biomarker levels in our study (Boston, MA) compared to the 
warmer climates of studies in North Carolina and Shanghai, China 30,36. 
Limited research has been conducted on OPE metabolites and male 
reproductive health.  However, we previously reported a decrease in sperm morphology 
(36%), straight-line velocity (18%), and curvilinear velocity (14%) in association with 
BDCIPP in a previous study of men (n=33) from the EARTH cohort.  The same study 
also reported decreased sperm concentration (57%) and straight-line velocity (19%) in 
association with urinary DPHP 23.  Similar relationships were detected in a study (n=50) 
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of their parent compounds in house dust where concentrations of TDCPP and TPHP 
were inversely associated with sperm concentration, motility, and morphology, although 
only the relationship between TPHP and sperm concentration was statistically 
significant (p=0.01) 32.   In this more robust analysis, we observed suggestive declining 
trends in our adjusted models among BDCIPP and DPHP with total sperm count and 
sample volume when modeled as continuous variables.  Our observations are 
inconsistent with previous work, possibly as a result of substantial sample size 
differences.   
Animal and in-vitro studies 
Laboratory studies assessing the reproductive impacts of OPEs are also limited, 
yet suggest OPEs act as endocrine disruptors and induce oxidative stress, both which 
have been associated with decreased sperm parameters 24,39.  Several in vitro models 
found TDCPP to be an estrogen agonist 40,41 while another found DPHP to have 
stronger estrogenic activity compared its parent compound (TPHP)42.  A study of mouse 
Leydig cells concluded TPHP failed to disrupt steroidogenesis, although increased  
TPHP concentrations resulted in a 1.7 fold increase in superoxide production 22.  
However, another study of mice found TCPP and TECP to alter antioxidant enzymes 
and testosterone levels 21.  Thus, although animal studies are limited, they suggest 
OPEs may potentially impact male fertility by altering reproductive hormones and 
impairing spermatogenesis via the hypothalamic-pituitary-gonadal (HPG) axis, or by 
disrupting the reactive oxygen species-antioxidant balance necessary for 




Although novel, our study is not without limitations.  While the largest study to 
date, our sample size is somewhat modest.  Few prior studies have assessed the 
predictors of OPE exposure in male populations, and our limited findings are potentially 
a result of parsimonious modeling combined with residual confounding.  Also, isolated 
exposure to OPEs among our sample is unlikely and simultaneous environmental 
exposures found to impact semen quality should be considered in future studies 43,44.  
Contrary to PBDEs which have a long half-life, OPEs are less-persistent and samples 
may be subject to more exposure misclassification since urinary metabolite levels may 
reflect exposure only hours or days prior to sample collection and we were unable to 
capture the time of urine sample collection.  However, we attempted to reduce this 
source of error by collecting up to five urine samples per participant and previously 
reported levels remain moderately stable over a three month period 18.   
 Men from a fertility clinic are a selective population that potentially limit their 
generalizability to the men from general population 7.  However, the semen quality of 
these men is comparable with the semen quality of men from the general population.  
Due to limited studies characterizing OPEs in male cohorts, we are unable to conclude 
the OPE concentrations found in our study do not reflect levels in the general population 
or that men from a fertility clinic would respond differently to OPE exposure.  Finally, 
while we analyzed five commonly used OPE  metabolites, there are other metabolites 
such as bis-2chloroethyl phosphate (BCEtP), di-n-butyl phosphate (DBNP), di-benzyl 
phosphate (DBzP), and di-cresyl phosphate (DCP) that should be the focus of future 




The results from our study characterizing the relationship between OPEs and 
male reproductive health are inconclusive.  Although our findings were inconsistent, we 
observed high detection of metabolites which coincides with previous and concurrent 
studies.  In comparison to our results and other studies, concentrations of OPE 
metabolites appear to be increasing over time.  Widespread detection rates, temporal 
increases in concentrations, along with evidence from animal research establish the 
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Table V.1. Demographic characteristics among 220 men from the Environment and 
Reproductive Health (EARTH) cohort. 
Characteristic N Mean or % SD  Median 25th, 75th 
quartiles 
Age 218 36.7 5.1  36.0 32.9, 39.9 
BMI 217 27.2 4.0  26.9 24.3, 29.1 
Abstinence period 186 3.9 13.9  2.4 1.8, 3.0 
       
Race 
   White 
   Black 
   Asian 











    
Smoking Status 
   Never smoke 
   Past smoker 









    
Education  
   <High school 
   HS grad 
   1 or 2 yr. college 
   3 or 4 yr. college 
   College grad. 















    
Season of sample 
   Winter 
   Spring 
   Summer 











    
SD: standard deviation; Missing: age, race, smoking n=2; BMI n=3; Abstinence period n=34;  
Education n=38; Season: n=335 using all observations; Winter: December-February, Spring: 




Table V.2. Distribution of semen parameters among 220 men from the EARTH cohort contributing 1-5 samples. 
 
   Percentiles 
Semen Parameter n Mean 10th 25th 50th 75th 90th 95th Max 
Total sperm 
count(mil/ejaculate) 
235 172.5 43.4 68.0 133.3 224.8 364.5 511.3 679.1 
Concentration (mil/mL) 237 77.02 15.9 30.2 58.2 110.1 140.5 156.5 617.4 
Motility (P+NP) (%) 237 44.30 10 25 45 63 75 80 93 
Progressive motility (%) 234 24.89 5 12 24 36 45 49 69 
Morphology (% normal sperm) 255 6.18 2 4 6 8 10 12 18 
Sample volume (mL) 267 2.68 1.0 1.7 2.5 3.5 4.5 5.1 8.7 












Table V.3. Distribution of uncorrected and Specific gravity corrected OPE metabolites (µg/L) of 220 men from                    










 MDL: Method detection limit; GM: Geometric mean; BCIPP data not shown (n=3 measurements)   
  
   Percentiles 
Uncorrected N >MDL, (%)   GM (95% CI) 25th 50th 75th 90th 95th Max 
   BDCIPP 285 (85.1) 0.62 (0.55, 0.71) 0.33 0.60 1.38 2.72 3.57 10.30 
   DPHP 289 (86.3) 0.78 (0.71, 0.87) 0.42 0.74 1.31 2.47 4.13 10.57 
   ip-PPP 223 (66.6) 0.35 (0.32, 0.39) <MDL <MDL 0.62 0.93 1.42 4.56 
   tb-DPHP 38 (11.3) 0.16 (0.12, 0.20) <MDL <MDL <MDL 0.38 0.73 2.24 
SG corrected         
  BDCIPP 285 (85.1) 0.64 (0.57, 0.73) 0.35 0.61 1.14 2.37 4.26 20.24 
  DPHP 289 (86.3) 0.77 (0.70, 0.84) 0.46 0.70 1.15 2.38 3.59 15.55 
  ip-PPP 223 (66.6) 0.32 (0.29, 0.35) <MDL <MDL 0.51 0.84 1.14 4.08 
  tb-DPHP 38 (11.3) 0.17 (0.12, 0.23) <MDL <MDL <MDL 0.50 1.58 1.87 
Specific gravity - 0.017 (0.016, 0.018) 1.011 1.018 1.024 1.027 1.028 1.038 
167 
 
Table V.4. Intraclass correlation coefficients (95% CI) for uncorrected and SG corrected repeated urinary                          
OPE metabolites (μg/L) among men from the EARTH cohort. 
 
 All samples a Excluding non-detects 
OPE Metabolite  Uncorrected SG corrected Uncorrected SG corrected 
BDCIPP 0.34 (0.20, 0.51) 0.21 (0.08, 0.45) 0.30 b (0.16, 0.50) 0.18 b (0.05, 0.47) 
DPHP 0.07 (0.00, 0.68) 0.09 (0.01, 0.62) 0.07 a (0.00, 0.68) 0.06 c (0.00, 0.81) 
ip-PPP 0.37 (0.24, 0.52) 0.25 (0.11, 0.49) 0.28 d (0.13, 0.48) 0.13 d (0.02, 0.55) 
∑OPE  0.17 (0.06, 0.42) 0.16 (0.03, 0.50) 0.13 e (0.00, 0.87) 0.67 e (0.45, 0.82) 
a n=335 samples from 220 men; b n=285 samples from 187 men; c n=289 samples from 200 men; d n=233                                
samples from 167 men; e n=192 samples from 145 men; Men contributing: 1 urine sample n=220, 2 urine samples                       

















Table V.5. Regression coefficients and odds ratios (95% CI) for semen parameters of men from the EARTH cohort 
contributing 1-5 urine samples. 
 
 OPE Metabolites a 
















0.70 -0.01 (-0.11, 
0.09) 
0.82 -0.04 (-0.14, 
0.07) 








0.96 0.005 (-0.09, 
0.10) 
0.92 -0.004 (-0.10, 
0.09) 








0.90 0.04 (0.05, 0.13) 0.40 0.12 (-0.08, 
0.11) 




motility a, d 
0.04 (-0.04, 
0.12) 
0.30 0.03 (-0.06, 
0.12) 
0.53 0.05 (-0.04, 
0.14) 







0.30 0.12 (-0.31,0.55) 0.58 0.21 (-0.21, 
0.64) 








0.45 -0.08 (-0.24, 
0.08) 
0.31 -0.04 (-0.20, 
0.12) 
0.61 -0.12 (-0.31, 
0.06) 
0.19 
             




b                                                            
0.79 (0.64, 
0.99) 
0.04 0.93 (0.55, 1.55) 0.78 1.04 (0.63, 
1.72) 






mil/mL c                                 
0.90 (0.72, 
1.13) 
0.37 0.97 (0.60, 1.57) 0.90 0.92 (0.54, 
1.57) 







g                                       
1.07 (0.86, 
1.35) 
0.53 1.13 (0.84, 1.51) 0.42 1.04 (0.79, 
1.38) 









c                             
1.05 (0.84, 
1.31) 
0.63 1.01 (0.76, 1.35) 0.92 0.90 (0.66, 
1.21) 





Sperm <4 e                                                  
0.92 (0.70, 
1.20) 
0.53 1.14 (0.83, 1.57) 0.44 0.94 (0.68, 
1.30) 
0.71 0.97 (0.66, 
1.42) 
0.86 
























Table V.6. Regression coefficients (95% CIs) by quartile of OPE metabolite for men from the EARTH                        
cohort contributing 1-5 urine     samples.   
 
 Semen Parameters 






n (mil/mL) a 
Motility 


















































































































































p-trend 0.42 0.97 0.91 0.37 0.26 0.38 
∑OPE   
Q1 (0.17-
0.79) 














































p-trend 0.62 0.56 0.11 0.05 0.25 0.52 
 
a natural log transformation; Quartile 1=reference.  Models adjusted for specific gravity, age, BMI, smoking status &                                   





Chapter V Appendix 
 
Table V.A.1. Crude bivariate associations with OPE and semen parameters among men (n=220) from the  
EARTH cohort. 
 
 OPE Metabolites 



















   Total sperm 
count 
0.06  0.36 0.08  0.34 0.07  0.37 0.08  0.67 
   Concentration 
(mil/mL) 
0.10  0.14 0.06  0.36 0.07  0.83 0.11  0.56 
   Motility (P+NP) 
(%) 
0.16  0.02 0.08  0.23 0.04  0.61 0.11  0.55 
   Progressive 
motility 
0.15  0.04 0.04  0.61 0.06  0.46 0.13  0.51 
   Morphology 
(%norm) 
0.09  0.21 -0.02  0.82 0.05  0.55 0.29  0.12 
   Sample volume 
(mL) 
-0.05  0.45 -0.05  0.43 0.004  0.96 0.14  0.45 
             
   Total sperm 
count  
   <39 mill a              
Yes 
                                










































   Sperm 
concentration   
   <15 mil/mL a       
Yes 










































   Percent motile 
sperm 












































   Percent morph.  
   Sperm <4 a            
Yes 















































Table V.A.2. Bivariate associations of OPE metabolite and demographic characteristics among men from the EARTH  
cohort (n=220). 
 
 OPE Metabolites 
































Age -0.04  0.54 -0.01  0.81 0.03  0.69 -0.15  0.38 
BMI 0.21  0.0005 0.08  0.15 0.04  0.49 -0.09  0.59 
Abstinence 
period 
0.07  0.27 0.01  0.89 0.08  0.26 0.14  0.45 
             
Race a 
  White 
   Black 
   Asian 



































































   Never 
smoke 
   Past smoker 





















































   <High 
school 
   HS grad    
   1 or 2 yr. 
college 
   3 or 4 yr. 
college 






















































































r= Spearman coefficient; a r = median values; Winter: December-February, Spring: March-May; Summer: June-August;                                      
Fall: September-November 
  












   Winter 
   Spring 
   Summer 






























































Table V.A 3.  Regression coefficients and odds ratios (95% CI) for semen parameters of men contributing (1-5) urine 




























a natural log transformation; b n=168; c n=188; d n=185; e n=204; f n=214.  Adjusted for specific gravity, age, BMI, smoking status & abstinence 




 OPE Metabolites  a 
 BDCIPP DPHP ip-PPP ∑ OPE  












0.49 0.05 (-0.07, 
0.17) 
0.42 -0.0001 (-0.11, 
0.00) 




(mil/mL) a, c 
-0.001 (-0.11, 
0.10) 
0.91 0.06 (-0.05, 
0.17) 
0.28 0.04 (-0.07, 
0.14) 




(%) a, c 
0.07 (-0.02, 
0.17) 
0.11 0.07 (-0.04, 
0.16) 
0.22 0.04 (-0.06, 
0.14) 




motility a, d 
0.07 (-0.04, 
0.17) 
0.21 0.06 (-0.06, 
0.17) 
0.32 0.06 (-0.05, 
0.17) 







0.11 0.22 (-0.26, 
0.70) 
0.36 0.26 (-0.19, 
0.711) 







0.20 -0.08 (-0.26, 
0.11) 
0.42 -0.06 (-0.24, 
0.11) 
0.47 -0.16 (-0.39, 
0.06) 
0.16 
             
Odds Ratio OR   OR   OR   OR   
Total sperm count 
<39 mill b                                                            
0.85 (0.63, 
0.85) 
0.33 0.90 (0.59, 
1.39) 
0.65 1.01 (0.55, 
1.84) 





mil/mL c                                 
0.88 (0.64, 
1.22) 
0.44 0.91 (0.57, 
1.48) 
0.70 0.98 (0.53, 
1.79) 





<40 b                             
0.94 (0.72, 
1.22) 








Sperm <4 e                                                  
0.89 (0.65, 
1.20) 
0.43 1.00 (0.72, 
1.39) 
0.99 0.92 (0.65, 
1.31) 





Table V.A 4. Intraclass correlation coefficients (95% CI) for repeated semen parameters 
among 220 men from the EARTH cohort. 
 
Parameter Subjects Observations ICC 95% CI 
Total sperm count (mill) 174 235 0.52 (0.36, 0.67) 
Concentration (mil/mL) 176 237 0.58 (0.41, 0.74) 
Motility (P+NP) (%) 176 237 0.79 (0.69, 0.86) 
Progressive motility 173 234 0.71 (0.58, 0.81) 
Morphology (%norm) 189 255 0.51 (0.35, 0.66) 






Table V.A.5. Odds ratios (95% CIs) by quartile of OPE metabolite for males from the EARTH cohort contributing 1-5 
samples.   
 
  Semen parameters 
 













BDCIPP   
Q1 (0.2-
0.17) 































p-trend  0.14 0.25 0.91 0.38 
DPHP   
Q1 (0.07-
0.27) 




































p-trend  0.83 0.91 0.96 0.24 
ip-PPP   
Q1 (0.04-
0.08) 


































p-trend  0.97 0.60 0.93 0.50 
∑OPE    
Q1 (0.17-
0.79) 
































p-trend  0.70 0.32 0.24 0.50 
a natural log transformation; Quartile 1=reference; Adjusted for specific gravity, age, BMI, smoking status  
















Summary of research findings 
 
 
     This dissertation highlights the lasting persistence of PBDEs and emerging presence 
of exposure to OPEs among a susceptible population.  Using a novel study design, we 
were able to evaluate preconception FR exposure of females and their partners with 
intermediate and clinical IVF outcomes.  Furthermore, our results also highlight the 
possibility of OPE use in consumer products.  A summary of the main research findings 
for each aim is presented in Figure VI.1.   
     In the first aim, we evaluated the associations of five PBDEs and four OH-BDEs with 
IVF endpoints among a subset of 215 women from the EARTH study.  PBDEs and OH-
BDEs were frequently detected despite being phased-out of production.  However, 
concentrations were highest for women recruited prior to 2010 compared to those who 
joined the study in 2010 or later.  We did not observe any trends with PBDEs and OH-
BDEs with intermediate IVF outcomes, although we identified some unexpected positive 
relationships of BDE153, 3 and 5-OH-BDE47, and 6-OH-BDE47 with implantation, 
clinical pregnancy, and live birth.  Concentrations of PBDEs and OH-BDEs were higher 
in Other race women compared to White women in our stratified analysis.  Despite 
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being underpowered, this provided insight to a possible racial disparity of PBDEs and 
reproductive health amongst Other race populations.  Trends for Other race women 
were negative while associations among White women remained positive.  BDE47 was 
associated with a decrease in the probability of implantation among Other race women.       
     The second aim expanded the first analysis to also include male PBDE and OH-BDE 
preconception concentrations among 189 couples.  Detection frequencies were high for 
several PBDEs and OH-BDEs and similar to their female partners’, concentrations for 
PBDEs and OH-BDEs were highest among men recruited in the early years of the study 
compared to those who joined in subsequent years.  However, concentrations were 
higher in females compared to their partners.  Correlations for congeners 47, 99, and 
100 were strongest among couples, yet weakest for BDE153.  Overall, no significant 
associations were observed for couple PBDE and OH-BDE exposure with IVF 
endpoints, yet some specific quartiles were associated with decreased probabilities of 
successful implantation, clinical pregnancy, and live birth.    
     The last aim focused on five OPE metabolites and was two fold.  We first 
investigated the association of reported consumer product use with OPE metabolite 
concentrations in urine among a subset of 230 women and 229 men from the EARTH 
cohort.  OPE metabolite concentrations were higher in women compared to men, yet 
metabolites BDCIPP, DPHP, and ip-PPP were frequently detected among couples.  
Correlations for metabolites among couples were weak.  Reported used of moisturizer, 
nail polish, and nail polish remover among women was associated with elevated DPHP 
concentrations while conditioner, cosmetics, deodorant, and hair product use were 
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associated with an increase in BDCIPP concentrations.  Mouthwash and vinyl glove use 
was associated with elevated DPHP concentrations in men.         
     In the final investigation, we evaluated the associations of OPE metabolites and 
semen parameters among a subset of 220 men from the EARTH cohort.  OPE 
concentrations among each participant varied over time.  Concentrations of BDCIPP 
samples varied by season and were 2-fold higher in the summer months compared to 
samples collected during other seasons.  We observed a positive association with 
BDCIPP concentrations and sperm count.  Although we identified some negative 
associations with sample volume and morphology in specific quartiles, overall 
associations were weak and inconsistent.  
 
 Integration of research findings   
 
     This dissertation uses a decade of data from couples seeking fertility treatment to 
provide insight to the persistence and possible associations of FRs with human 
reproduction.  While concentrations of PBDEs and OH-BDEs declined over time, we 
observed a slight increase in OPE metabolite concentrations.  Although overall 
associations with FRs were not significant, several overarching themes emerged from 
this dissertation: 
1) Concentrations of PBDEs decreased over time while OPE metabolite 
concentrations remained relatively stable.  A strength of this dissertation 
work is the benefit of monitoring the implications of a chemical phase-out during 
the study period.  In the mid-2000s PentaBDEs were voluntarily removed from 
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products 1.  Although PBDEs bioaccumulate in our bodies and the environment, 
concentrations decreased over time for both women and their partners.  
However, among women we observed a steady decrease over the ten-year 
period with a noticeable drop in 2010 until the end of recruitment.  We did not 
expect to observe a different trend among the male partners.  Although 
concentrations decreased, the largest drop in concentrations occurred between 
2006-2007 while concentrations remained stable for the remainder of the study 
period.  While the phase-out is likely a result of declining concentrations among 
couples, it was unexpected to observe such a divergence in temporal trends of 
concentrations.  As PBDE concentrations declined, we expected concentrations 
of OPE metabolites to increase, a trend which had been observed in a prior 
study of adults and children in the US 2.  However, metabolite concentrations for 
women and their partners remained relatively stable over the study period with a 
slight increase in BDCIPP in 2013 (Figure IV.2).  Although we established some 
associations with OPE metabolites and consumer product use, it is possible that 
participants had not replaced old furniture, carpeting, etc. or they may have 
replaced these items with products that were FR free.   
 
2) Higher FR concentrations in women compared to their male partners.  
Interestingly, we observed statistically significant higher concentrations of all 
FRs and metabolites for women compared to their male partners.  Similarly, 
correlations for each FR and metabolite was also weak among couples.  Weak 
correlations and differences in OPE metabolite concentrations is possibly due to 
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the rapid metabolism of parent compounds once in the body, or as we observed 
in the third aim, OPE exposure could be attributed to consumer product use 
which can be both episodic and vary by gender 4,5.  However, considering the 
common sources of exposure for PBDEs among couples (i.e. indoor 
environments), the differences in exposure were unexpected 6.  However, some 
studies have observed varying PBDE concentrations in different rooms of a 
house 7.  It is also possible the differences in concentrations arise from separate 
workday environments, as it is unlikely that couples also work in the same 
location together.  Differences in BDE153 have been associated with specific 
diets which could possibly account for the difference in concentrations and the 
weak correlations, as diets vary by individual 8.  Interestingly, unadjusted PBDE 
and OH-BDE concentrations were comparable among women and men and we 
also observed statistically higher BMI and lipid levels in men compared to 
women.  Therefore, lipid concentrations may be vital in PBDE and OH-BDE 
exposure.  Lipid peroxidation may be increased in women during IVF which may 
activate a release of chemicals within fat stores 9.                
 
3) Unexpected positive associations of female PBDE and OH-BDE 
concentrations with clinical IVF outcomes.  The hypothesis from the first aim 
was established from several existing laboratory studies that had observed 
greater toxicity among OH-BDEs compared to PBDEs, yet our results were 
contrary to those findings.  Not only were associations positive for PBDEs with 
clinical outcomes, associations with OH-BDEs were positive and at a greater 
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magnitude than PBDEs.  The positive results were unexpected yet do not 
remain when accounting for male exposures.  Unmeasured confounding 
regarding diet is possible as some OH-BDEs are organically produced in marine 
environments 10.    Finally, the continued increase in IVF success rates over 
time could have also biased our results in both female and couple models by 
overestimating the positive relationship between successful implantation, clinical 
pregnancy, and live birth rates with PBDE and OH-BDE concentrations 14. 
 
4) The inclusion of male exposure when evaluating the relationships of 
environmental toxicants and infertility is essential.  While there are many 
existing cohorts assessing the impact of environmental toxicants and 
reproductive outcomes among women 15–17, few reproductive health studies 
focus on either male or couple exposure, yet primarily focus on TTP 18–21.  The 
EARTH study design enables the assessment the associations of preconception 
exposure of environmental toxicants with reproductive endpoints from 
preconception to live birth.  Merely accounting for female exposure could 
possibly over or underestimate the impact of a chemical exposure on fertility 
and pregnancy outcomes.  In the second aim, when also accounting for male 
exposure, the positive results with implantation, clinical pregnancy, and live birth 
diminished and lost statistical significance.  The addition of male exposure also 
increases the ability to evaluate a larger scope of the possible mechanisms of 




 Impact and innovation  
     Human reproduction is a composite of multiple biological responses, many of which 
typically occur without observation.  Epidemiologic studies assessing infertility solely 
through fecundity and TPP in the general population fail to distinguish the many 
endpoints between pre-conception and live birth.  Using a population undergoing IVF 
allows for the capture of intermediate as well as clinical birth outcomes.  Isolating each 
endpoint allows us to differentiate critical windows that may inhibit fertility.  Also, this 
dissertation incorporates, the contribution of PBDEs and OH-BDEs exposures as a 
‘couple,’ to better elucidate the role of exposure from both sexes during reproduction.  
Assessing the relationship between male and female exposure also provides insight to 
possible routes or exposure pathways and potential diverging mechanistic pathways.  
Correlations among all FRs and metabolites were weak among couples and suggests 
distinct sources of exposure per individual, especially in respect to those living in the 
same household.  Using data spanning nearly a decade, this dissertation work was able 
to assess the temporal trends of a class of chemicals undergoing a phase-out as well as 
the addition of an alternative compound.  Our use of CWGEE to model the relationship 
of PBDEs and OH-BDES with clinical outcomes is a novel statistical approach to 
provide more precise effect estimates while accounting for multiple cycles per women or 
couple 22.  Finally, studies assessing the relationship between OPEs and consumer 
products are limited 4,23.  Our comprehensive analysis assessed the relationship of PCP 
and HP with OPE metabolites.  Our findings of positive associations between OPE 
metabolites and use of several PCPs among women facilitates future, more specific 





Recommendations for future research  
 
     This dissertation has several strengths including novel study design, innovative 
statistical methodologies, and targeted assessment of a susceptible population which 
contributes to the current scientific body of evidence of FRs and human reproduction.  
However, our comprehensive results and study limitations provide opportunities for 
future research: 
1) Target more diverse IVF study populations.  Patients from fertility clinics often 
have limited ethnic and racial diversity.  The high cost of IVF and few states with 
insurance mandates for fertility treatment typically limit studies to highly 
educated, primarily White participants.  The demographics from our sample 
follow these assumptions with approximately 80% of patients identifying as White 
and most having a college or graduate degree.  One study in the United Kingdom 
(UK) of over 13,000 first IVF cycles observed poorer IVF outcomes among Black 
women compared to White 24.  Higher PBDE and OH-BDE concentrations have 
been observed among Black women compared to White women in a cohort in 
CA 25.  Unfortunately, our sensitivity analysis stratifying by race was 
underpowered, yet associations with clinical outcomes became negative when 
stratified for Other race women.  It is possible that a larger and more diverse IVF 
population could provide insight to a possible racial disparity among the 
relationship of PBDE and OH-BDEs with fertility.   
2) Reproductive toxicity of emerging FRs and FR mixtures.  This dissertation 
concentrates on two primary classes of FRs, yet there are several others 
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including halogenated FRs, novel brominated FRs (NBFRs), and dechlorane 
which have all been detected in indoor dust samples 26,27.  Human studies 
evaluating the association of these alternative FRs are limited, yet mixtures of 
bis(2-ethylhexyl)-2,3,4,5-tetrabromophthalate (TBPH) and 2-ethylhexyl-2,3,4,5 
tetrabromobenzoate (TBB) have been associated with reduced fecundity among 
Japanese medaka 28.  Despite the crucial necessity to understand the specific 
relationships between individual FRs and human reproduction, as multiple FRs 
are highly detected across the general population, a comprehensive 
understanding of the reproductive toxicity of FR mixtures is necessary.  
Furthermore, the understanding of how our complex daily microenvironments of 
mixtures including but not limited to: FRs, phthalates, metals, and particulate 
matter comprehensively impact reproductive health is also essential.   
 
Final comments  
  
     This dissertation highlights the continued persistence of PBDEs and their 
metabolites, despite their being phased out of production.  However, this longitudinal 
analysis was able to capture temporal trends using ten years of FR exposure sample 
collection to provide perspective of declines in PBDE concentrations and slight 
increases of OPE concentrations among couples seeking fertility treatment.  Although 
our results were unexpected, few studies to date have investigated the association of 
OH-BDEs and reproductive health.  Furthermore, our novel study design underscores 
the importance of considering male exposures when evaluating the relationships of 
environmental toxicants with fertility and pregnancy outcomes.  The third aim of this 
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dissertation illustrates the cyclical relationship of harmful substitution chemicals and 
demonstrates their use in products other than as a FR.  This study was also the most 
comprehensive analysis of consumer products and OPE metabolites.  We observed 
several associations of metabolites with consumer product use among men and 
women.  It is possible consumer product use also contributes to internal OPE exposure.  
Although FRs were initially developed to provide important safety benefits, this work 
contributes to the growing body of evidence of the persistence and possible 
reproductive health effects of FRs and calls for the development of safer alternatives or 
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Figure VI.1. Conceptual diagram of specific aims, main research findings, and public health impact. 








Aim 1 & 2 
• Widely detected among couples 
• Higher PBDE & OH-BDE 
concentrations in women vs. men 
• PBDE concentrations decreased 
over time 
• Unexpected positive associations 
with clinical outcomes were 




• Widely detected among couples 
•  Higher concentrations in women 
vs. men 
• Consumer product use was 
associated with higher 
concentrations of metabolites 
fertility treatment 
• Important to consider male exposure when  
evaluating the reproductive toxicity of chemicals 
• OPEs found in consumer products may contribute to 
internal exposure 
Public health impact 




• Important to consider 
male exposure when 
evaluating the 
reproductive toxicity of 
chemicals 
• OPEs found in 
consumer products 




Figure IV.2. Geometric means of OPE metabolite concentrations (µg/L) stratified by year of sample collection   among a 
subset of men (n=229, n=335 urine samples) and women (n=230, n=638 urine samples) from the EARTH cohort. 
 
 
